Does an Advanced Electronic Tracker Help Families Manage Children's Asthma Symptoms Better Than a Standard Electronic Tracker?

Flory L. Nkoy MD MS MPH, 1 Bernhard A. Fassl, MD, 1 Victoria L. Wilkins, MD, MPH, 1 Joseph M. Johnson, MD,2,3 Eun Hea Unsicker, MPH, 1 Karmella J. Koopmeiners, RN, MS 3, Andrea Jensen,4 Michelle Frazier,4 Jordan Gaddis,4 Lis Malmgren,4 Stacey Williams,4 Justin B. Poll, PhD, 3 Tom H. Greene, PhD, 1 Xiaoming Sheng, PhD, 1 Derek A. Uchida,1 Christopher G. Maloney, MD, PhD, 5 Bryan L. Stone, MD, MS, 1

1 University of Utah Hospital, Salt Lake City, UT
2 Johnson Pediatrics, Provo, UT
3 Intermountain Healthcare, Salt Lake City, UT
4 Parent Partners, SLC, Utah;
5 University of Nebraska at Omaha, Omaha, NE

Original Project Title: Redesigning Ambulatory Care Delivery to Enhance Asthma Control in Children
PCORI ID: IH-12-11-5330
HSRProj ID: 51002874
ClinicalTrials.gov ID: NCT02409277

Table of Contents

ABSTRACT .............................................................................................................................. 4
BACKGROUND .......................................................................................................................... 6
PARTICIPATION OF PATIENTS AND OTHER STAKEHOLDERS IN THE DESIGN AND CONDUCT OF RESEARCH AND DISSEMINATION ................................................................. 10
  C.1. Parent/Stakeholder Engagement in the Current Proposal ........................................ 10
  C.2. Methods to Identify/Recruit Parents/Stakeholders .................................................. 10
  C.3. Engagement Frequency ............................................................................................. 11
  C.4. Perceived or Measured Impact of Parent/Stakeholder Engagement ....................... 11
  C.5. Study Rigor and Quality ............................................................................................. 12
  C.7. Adoption of Research Evidence Into Practice ............................................................ 13
METHODS .......................................................................................................................... 14
  D.1. Setting/Initial Design/Objectives ............................................................................... 14
  D.2. Study Design Change/Updated Objectives ............................................................... 14
  Figure 2. Study design and randomization procedures .................................................... 15
  D.3. Forming the Study Cohort ......................................................................................... 16
  D.4. Interventions ............................................................................................................. 18
  D.5. Follow-up ................................................................................................................... 22
  D.6. Study Outcomes ........................................................................................................ 23
  D.7. Data Collection and Sources ...................................................................................... 23
  D.8. Statistical Analysis ..................................................................................................... 25
  D.9. OBJECTIVE 1: Assess the Effectiveness of the New Ambulatory Care Model ........... 28
        D.9.1. Descriptive Analyses: .............................................................................................. 28
        D.9.2. Randomized Comparisons Between Standard and Intensive e-AT Interventions:
                  See Figure 2 ...................................................................................................................... 28
        D.9.3. Five Nonrandomized Comparisons Between e-AT Interventions vs Usual Care ... 30
  D.10. OBJECTIVE 2: Assess Whether the Effect on Child Outcomes Varies Across Parent Characteristics (High vs Low Education, Medicaid vs Private Insurance, Frequent vs Infrequent Users) .............................................................................................................. 34
  D.11. OBJECTIVE 3: Determine Factors Associated With Sustained Parent Participation in Asthma Self-management ......................................................................................................................... 35
  D.12. Strategies for Handling Missing Data ...................................................................... 36
  D.13. Conduct of the Study ............................................................................................... 36
RESULTS ............................................................................................................................. 37
**ABSTRACT**

**Background**
We implemented the electronic-Asthma Tracker (e-AT) at 11 clinics to support a new ambulatory care model for children with asthma. The e-AT is a web and mobile web, user-friendly tool designed to engage parents in monitoring their child’s asthma, with real-time alerts and recommendations to promote timely care.

**Objectives**
(1a) Compare outcomes between clinics randomized to standard vs intensive e-AT intervention. (We initially planned a cluster randomization but modified the study design per stakeholders’ request, allowing all participants to receive the e-AT).
(1b) Use nonrandomized comparisons to determine the e-AT effectiveness vs usual care.
(2) Assess whether the e-AT effect on child outcomes varies across parent characteristics.
(3) Determine factors associated with sustained parent participation in self-management.

**Methods**
Participants 2-18 years old were enrolled between January 1, 2014, and December 31, 2015, with a 1-year follow-up. e-AT (standard) implementation was staggered, with 6 clinics starting early (January 1, 2014) and 5 late (April 1, 2014), with 3 months’ delay. On September 17, 2014, 5 clinics (3 early and 2 late) were randomized to continue with the standard e-AT and 6 clinics (3 early and 3 late) to transition to intensive e-AT. We used prespecified analyses, including randomized comparisons between clinics on the standard (n = 261) vs intensive (n = 57) e-AT. Nonrandomized comparisons included the following:
(1) longitudinal change within-subjects (n = 318);
(2) emergency department (ED)/hospital admissions/oral steroid use (n = 325) in the year following vs prior to patient’s enrollment (pre–post);
(3) ED/hospital admissions/oral steroid use in patients in early (n = 198) vs late (n = 129) starting clinics (clinic-level) with the 3-month delay (or usual care period);
(4) ED/hospital admissions/oral steroid use in patients (patient-level) who started the e-AT in the first year (January 2014-December 2014) or early starting patients (n = 234), during the 1-year period after e-AT start dates vs those starting the e-AT in the second year (January 2015-December 2015) or late starting patients (n = 91), during the 1-year period prior to e-AT start dates (usual care); and
(5) ED/hospital admissions/oral steroid use in e-AT participants (n = 325) vs nonrandomized matched controls from clinics that did not use e-AT (n = 603).

**Results**
We enrolled 325 children and parents. Average e-AT use adherence was 65% at 12 months. In randomized analyses (analysis 1), we found no differences in outcomes of intensive vs standard e-AT. When compared with their own baseline (analysis 2), e-AT participants had (P < 0.001)
increased quality of life (QOL), reduced missed school/work days at 3, 6 and 12 months, and increased asthma control at quarters 1 to 4. Parent satisfaction remained high. ED/hospital admissions and oral steroid use (analysis 3) were reduced ($P = 0.024$ and $P = 0.003$, respectively) in the year post vs year prior to patient’s enrollment. We found only 2 patients in early starting clinics with ED/hospital admissions and 4 who used oral steroids, during the 3-month delayed start of late-starting clinics, too few for statistical analysis (analysis 4). We found no differences in ED/hospital admissions ($P = 0.183$) and oral steroid use ($P = 0.937$) between early starting vs late starting patients (analysis 5). Relative to matched controls from clinics that did not implement e-AT (analysis 6), e-AT participants had reduced ED/hospital admissions ($P = 0.004$) and oral steroid use ($P = 0.019$). Finally, having Medicaid insurance was associated with higher ED/hospital admission risk, with some QOL reductions on more educated but infrequent e-AT user parents. Barriers and facilitators of e-AT use were identified.

**Conclusions**
The e-AT was effective in improving asthma outcomes. Dissemination can improve asthma care broadly.

**Limitations**
Resulted from study design change, replacing a cluster randomization design and relying on nonrandomized comparisons to assess the e-AT effectiveness relative to usual care.
BACKGROUND

Pediatric asthma is associated with frequent exacerbations (attacks) and a significant impact on a child and family’s quality of life (QOL) and health care utilization.\(^1\) In 2009, an estimated 7.1 million children younger than 18 years of age had asthma.\(^1\) Asthma is also one of the most common causes of school absenteeism and missed work for parents.\(^2\) The annual economic impact of pediatric asthma in the United States is estimated at $20.7 billion in total costs.\(^3\)

Despite guidelines, asthma remains a poorly controlled disease.\(^4\) Poor control leads to increased risk for asthma attacks, poor QOL, and frequent acute health care use.\(^5\) To improve control and reduce asthma attacks, asthma guidelines recommend patient self-management.\(^6-9\) Asthma self-management support interventions have focused mostly on adults\(^10-16\) and have been associated with improved outcomes.\(^13,14,16-20\) However, self-management support interventions in children remain rare and are challenging to achieve.\(^7\)

The few studied self-management support interventions in children have limitations. They have (1) been complex and required a significant amount of staff time, creating physician practice operational challenges\(^21\); (2) rarely included regular monitoring with timely feedback; (3) not effectively engaged parents and primary care providers (PCPs); and (4) either not evaluated the effect on asthma outcomes\(^22,23\) or reported mixed results with no effect \(^21,24-27\) or little effect on outcomes.\(^28,29\) Also, children are less able to verbalize complaints.\(^30\) Their subtle complaints often go unrecognized by parents,\(^31\) who often are unaware of early signs of deterioration\(^31,32\) and lack effective tools to guide them in recognizing and acting on warning signs of deterioration.\(^33\)

Several validated tools exist to assess asthma control and support self-management. Spirometry is limited by availability, cost, and effort required by younger children to perform the test.\(^7\) Peak flow (PF)\(^34\) is effort-dependent and is not always reproducible over time.\(^7,35-37\) Symptom-based questionnaires like the Asthma Control Questionnaire (ACQ) or Asthma Control
Test (ACT) have equal validity with PF, but with several limitations. Our team addressed
limitations of symptom-based questionnaires and was the first to validate the ACT as a weekly
self-management tool (within Asthma Tracker) for use by children or parent proxies.

This project was built on our previous efforts to transform and improve asthma care,
beginning with the development and validation of the paper-Asthma Tracker (paper-AT) and
moving to the design, validation, and pilot testing of the electronic-Asthma Tracker (e-
AT). The paper-AT is a user-friendly tool we developed in 2010 to engage parents in their
child’s asthma self-management, using the ACT questionnaire, adapted and validated for
weekly assessment of asthma control and augmented with a longitudinal graphical display of
weekly ACT scores, and coupled with decision support to guide appropriate and timely
responses by parents/children and PCPs to warning signs of asthma control deteriorations.
Although the paper-AT tool was successful in improving asthma outcomes in our preliminary
study, there were limitations. Specifically, there was no real-time feedback for
patients/parents, who had to interpret results themselves based on preset recommendations.
This approach delayed the time for identifying early signs of asthma control deteriorations, for
at least 1 week. There was also a lack of incentive to engage patients/parents in sustained use,
particularly if their child’s asthma was well controlled. Thus, parents thought a web or mobile
phone version would be more useful in engaging them.

With parent stakeholders, we developed the e-AT (http://asthmatracker.utah.edu) to
address limitations of the paper-AT by providing (1) parents with immediate prompts when
their children are doing well and early warnings when an action or a PCP visit is needed, (2)
PCPs with objective and real-time patient data to guide appropriate adjustments of asthma
therapy, and (3) longitudinal patient data to monitor disease progression. The e-AT can be used
by older children with or without parental assistance or by parents of younger children (< 11
years old). In our initial focus group, parents were interested in assessing the e-AT effectiveness
and identifying critical barriers associated with sustained e-AT use. Factors associated with
sustained use of self-management support interventions are not well known. Knowing these factors would help promote uptake of these interventions.

Our goal was to implement the e-AT at multiple clinics and assess the impact on outcomes. We hypothesized that participants/clinics in the intensive e-AT would have better outcomes. In addition, participants/clinics in the new care model (both standard and intensive e-AT) would have better outcomes relative to usual care. We also hypothesized that child outcomes would be better in parents who were frequent e-AT users with a high health literacy as well as private insurance, but that they would be similar in frequent e-AT users, regardless of parent characteristics. Finally, we hypothesized that sustained parental participation in asthma self-management would be influenced by prespecified factors (Figure 1) guided by the literature and that crosscutting themes (barriers and facilitators), generalized to other chronic diseases, would be identified across demographic and socioeconomic factors.
Figure 1. Conceptual framework of the relationship between factors and parent participation

Socio-demographic Factors
- Age
- Sex
- Marital Status
- Location (rural vs. urban)
- Parental Occupation
- Parental Education

Behavioral Factors
- Attitudes/Beliefs
- Motivation
- Autonomy/Control
- Knowledge/Understanding
- Self-efficacy
- Self-care Attitude
- Family Support
- Peer Support

Socio-economic Factors
- Parental Income
- Employment Status

Technology Factors
- Timeliness
- Usefulness
- Information Satisfaction
- Format
- Accuracy
- Ease of Use
- Completeness
- Reliability

Participation in Self-management

Outcomes

Treatment
C.1. Parent/Stakeholder Engagement in the Current Proposal

We engaged 10 parents of children with asthma in the design and validation of the paper-AT. While developing the current proposal, we worked with 1 parent representative who used the paper-AT for her child. Upon funding, we recruited 5 more parents for a total of 6 parents. We also engaged 2 PCPs to provide insight in facilitating e-AT implementation at clinics. We also involved other stakeholders, including representatives from insurance companies (Select Health and Medicaid), the Utah Department of Health (school nurse and asthma program), and the Intermountain Healthcare (IH) system (pediatric and primary care clinical program directors), as well as an external advisory committee of recognized health care leaders. Overall, we engaged 16 parents and 13 stakeholders to solicit their input in designing and testing the paper-AT and e-AT, and in developing the current proposal, including objectives, study design, and outcome measures. Input was received through focus group sessions and facilitated discussions.

C.2. Methods to Identify/Recruit Parents/Stakeholders

We recruited parent partners from a cohort of parents of children who used the paper-AT. To ensure a good representation in characteristics that could affect participation, we divided parents into 2 groups based on their adherence with weekly use of the paper-AT, and selected 2 frequent and 2 infrequent users. We also solicited referral from PCPs, who helped us enroll 2 more parents. We recruited community stakeholders based on established relationships from previous collaborations.
C.3. Engagement Frequency

After funding, we held a 2-day kickoff retreat with all stakeholders. We watched 2 PCORI videos on stakeholder engagement in research and discussed expectations regarding their participation and required trainings (eg, Human Subject Protection, HIPAA). We discussed the provisional study protocol for additional stakeholder input, reviewing and recording direction regarding study objectives, design, and outcome measures. During the study, we held monthly meetings with clinic care coordinators (CCCs), parents, and the research team, and quarterly meetings with the entire team to discuss progress and issues raised in the study. Other parent engagement activities included (1) developing clinic/participant recruitment materials, (2) participating in monthly research progress conference calls, (3) reviewing performance data and assisting in solving issues, (4) monitoring project goals and providing ongoing support, and (5) conducting site visits to address barriers to study recruitment. The advisory community members were included in the various work phases, providing their input through phone calls or emails, or via face-to-face meetings (2 times per year).

C.4. Perceived or Measured Impact of Parent/Stakeholder Engagement

*Development of the research questions*: As stated above during the e-AT pilot test, parents motivated us to develop our study questions focusing on e-AT effectiveness and in identifying barriers to sustained e-AT use.

*Study design and processes*: We originally planned to cluster randomize clinics to the e-AT intervention or usual care and compare outcomes. However, during our kickoff retreat (before we launched the study), our stakeholders strongly opposed withholding the e-AT intervention from control clinics and patients, given our preliminary data showing asthma outcome improvements. *(Note: Our team previously pilot tested the e-AT effectiveness in a prospective study of children aged 2-12 enrolled during asthma hospitalization: 210 e-AT users vs 353 nonusers (controls). The e-AT was used weekly for 6 months posthospital discharge. Overall, e-AT users had longer time to first readmission. Our study also demonstrated a direct*
dose-effect relationship with frequent e-AT users having fewer ED/hospital admissions than less frequent users). Specifically, our stakeholders requested changing the study design to allow all clinics to use the e-AT (see also Section D.2). They also requested a change in the enrollment age criteria (from 2-12 to 2-17 years old) to include teenagers, a population with high asthma morbidity and poor adherence to treatment. Finally, they requested changes to a few outcomes (eg, from missed school/work days to interrupted or missed school/work days), reflecting the parental reality that their days were often interrupted due to their child’s asthma. PCORI staff approved their suggestions, and changes were made before the study started.

**Selection of outcome measures:** Child’s QOL, the primary outcome (objective 1), was selected to capture 2 of the most relevant asthma outcomes that parents were concerned about, including nighttime awakenings and activity limitations. Children who are awakened at night due to asthma are often tired during the day and have more difficulty concentrating in school. In addition, parents are affected by productivity reduction due to lost sleep. Secondary outcomes reflected parent/stakeholder interest in improving asthma control, satisfaction with care, and avoiding ED/hospital admissions. As stated earlier, our research questions also focused on identifying and addressing barriers to sustained e-AT use. We also included assessment of the e-AT effectiveness across different parent characteristics (objective 2) and critical factors associated with sustained parent participation in asthma self-management (objective 3).

**C.5. Study Rigor and Quality**

Although stakeholder engagement led to the selection of outcome measures that were meaningful to them, changes to the initial design (due to stakeholders’ request) to allow the e-AT to be provided to all participants and clinics, reduced the rigor and quality of the study and led to a more complex study design (see Methods section).
C.6. Transparency of the Research Process

We engaged parents and other stakeholders through the entire research process. All major decisions regarding the study process were made with parent partners and stakeholders, often using language understandable to them, leading to increased transparency. We can share upon request the study documentation (eg, study protocol, programming code and data definitions) and deidentified data, so others may reproduce results.

C.7. Adoption of Research Evidence Into Practice

Parent stakeholders were eager to facilitate clinic recruitment based on their own experience using the e-AT. They also worked to improve participant’s adherence by developing patient recruitment materials and a Facebook page to strengthen parent support and to increase their ability to sustain ongoing use of the e-AT and study participation. Their presence during clinic recruitment and outreach visits increased the study’s credibility and motivated clinic participation.
METHODS

D.1. Setting/Initial Design/Objectives

The study involved 11 primary care clinics, with 9 clinics belonging to the IH system. These clinics are located in Salt Lake City and rural regions in northern and southern Utah. IH is a regional, not-for-profit integrated health care delivery system, with 22 hospitals and 185 clinics and urgent care facilities in Utah and southeastern Idaho, providing care to ~1 680 000 patients, which includes ~60% of Utah’s residents and 85% of Utah’s children.50 We enrolled children 2-17 years old with persistent asthma and their parents. The study was initially a prospective, cluster-randomized trial with 480 children (2-12 years old) and parents from 10 clinics to be randomized to the e-AT vs usual care.

D.2. Study Design Change/Updated Objectives

We made changes (see detail under C.4) to the study design, age criteria, and outcome measures, and one clinic was added (making 11 clinics), leading to a new design with staggered implementation of clinics, split in 2 groups, early (started on January 1, 2014) vs late (started on April 1, 2014) starting clinics, with a 3-month delay period between the 2 starting dates. We then cluster-randomized clinics to standard vs intensive e-AT. Figure 2 illustrates the updated study design.
Final objectives included the following:

**Objective 1:** To assess the effectiveness of the new ambulatory care model, by comparing outcomes for the (1a) child (QOL, asthma control, and interrupted/missed school days due to asthma); (1b) parent (satisfaction and interrupted/missed work days due to a child’s asthma); (1c) clinic (ED/hospital visits due to asthma), between clinics randomly assigned to the standard vs intensive e-AT intervention; and (1d) use of several nonrandomized comparisons to determine the e-AT effectiveness relative to usual care periods or control groups (see Section D.9.3. for detail) in which the e-AT was not used.
**Objective 2:** In the intervention groups, to assess whether the effect on child outcomes varies across parent characteristics (high vs low health literacy, Medicaid vs private insurance, frequent vs infrequent users).

**Objective 3:** In the intervention groups, to determine (demographic, socioeconomic, behavioral, and technology) factors associated with sustained parent participation in asthma self-management (defined as sustained use of the e-AT).

**D.3. Forming the Study Cohort**

We conducted an outreach visit and education at clinics that met the eligibility criteria and showed interest to participate in the study.

*Clinic eligibility:* Primary care clinics with (1) capacity (eg, available CCCs and time) and leadership to adopt e-AT, (2) patients < 18 years old with persistent asthma, and (3) capacity to accommodate patient enrollment and training about e-AT use.

Not all IH clinics were contacted for participation. Of the 11 clinics contacted and accepted to participate, 9 are part of the IH system. PCPs from the 2 non-IH clinics are familiar with the IH systems and asthma care process model, as they admit and see their patients hospitalized at their reference local IH hospitals.

*Clinic training:* Clinics (including PCPs, nurses, CCCs, and other clinical staff) received an introductory presentation about gaps in asthma care, the e-AT application, how it can be implemented in the clinic, how it can guide step therapy, and results of a pilot study. The CCCs also received one-on-one training with the research coordinator on how to enroll, monitor (using the dashboard), respond to alerts, and follow up with patients in collaboration with the patient’s PCP.
**Participant eligibility:** Inclusion criteria were as follows: (1) children 2-17 years old with persistent asthma and their parents (patient’s eligibility was verified first using the enterprise data warehouse (EDW), with persistent asthma defined as being on a controller medication, and then from physician documentation in the medical records of persistent asthma [based on NIH classification criteria]); (2) English speakers; (3) children who had received asthma care at participating clinics; and (4) families with internet access.

As this was a pragmatic trial in a real clinical environment, no patients were excluded, except those who had previously used the paper-AT.¹

**Participant identification/enrollment:** Eligible participants were identified (as described above) by each clinic and approached for enrollment (in standard e-AT) in early (January 1, 2014) or late (April 1, 2014) starting clinics, using 2 processes: (1) phone calls by the clinic CCC, inviting them to the office for enrollment; and (2) direct CCC invitation during clinic visits (asthma or non–asthma related). Clinics were randomized (on September 17, 2014) to standard vs intensive e-AT. Participants who consented were educated about the e-AT using a standardized teaching flipchart, given e-AT access with a temporary username/password to be changed at first login, and asked to use the e-AT weekly for a 1-year period after enrollment. Participant enrollment occurred from January 1, 2014, to December 31, 2015.

Control groups (see section D.9.3) included (1) late starting clinics (vs early starting clinics), (2) late starting patients (vs early starting patients), and (3) matched controls drawn

---

¹ As stated in the Background section, our efforts to improve ambulatory asthma care began with the development [in 2010] and validation of the paper-AT and moved to the design [in 2012] and pilot testing of the e-AT.²³⁴ The paper-AT is a user-friendly tool that engages parents in their child’s asthma self-management. We developed it by using the ACT questionnaire,²⁷ which we adapted and validated for weekly assessment of asthma control. We augmented the paper-AT with graphical display of weekly ACT scores, coupled with decision support to guide appropriate and timely responses by parents/children and PCPs to early signs of asthma control deteriorations. The e-AT addresses the paper-AT limitations by adding real-time feedback and alerts to parents and PCPs.⁴⁶
from 42 nonparticipating clinics within the IH system located in Salt Lake City and Utah County, where randomized clinics are located.

**Participant withdrawal:** Participants who elected to withdraw from the study had no data collected after the withdrawal date. Data collected prior to withdrawal remained in the study database. Research personnel contact information was available to participants during the study to facilitate communication and decision to withdraw.

Clinics did not collect reasons why participants declined enrollment, although they reported that most (> 90%) accepted participation. Only 9 patients/families decided to withdraw, for 3 reasons: (1) lack of time (n = 1), (2) misdiagnosis of asthma (n = 1), and (3) because they were no longer interested in the study (n = 7).

D.4. Interventions

**Comparator control intervention/rationale for selection:** The e-AT was chosen because parents were interested in its effectiveness. We have 2 levels of comparisons: (1) standard vs intensive e-AT and (2) e-AT interventions (standard/intensive) vs nonrandomized usual care. Asthma care at these clinics (e-AT and non-e-AT) is standardized through prior quality improvement projects. (Although the other 2 clinics are from non-IH systems, their PCPs also work at IH hospitals and have been involved with various quality improvement projects implemented by Intermountain to standardize asthma care.) Usual care was directed by national guidelines, with rescue therapy for acute symptoms, controllers (medications for long-term control of asthma symptoms) based on asthma severity/control (step therapy), asthma education, and a written action plan.

**Standard e-AT intervention:** The e-AT, web (Figure 3) and mobile web (Figure 4) versions have 4 components: (1) patient portal, (2) survey questionnaire, (3) report generator creating color- colored dynamic run charts (Figure 5), and (4) decision support pop-up messages/recommendations) tied to asthma control scores, displaying green, yellow, and red
zones, with personalized feedback (email/text messages tailored to each patient). The standard e-AT features include (1) automated reminders to sustain use; (2) real-time result graphing; and (3) alerts that are sent to patients/parents (via email/text messages) and the PCP’s office (via clinic email and e-AT clinic web-based dashboard) on the patient’s deteriorating asthma control; and (4) real-time decision support (pop-up messages recommending appropriate actions) based on color zones: green (continue current care), yellow (follow asthma action plan, and contact PCP if score remains in the yellow zone the following week), and red (contact PCP immediately for evaluation). The dashboard (Figure 6) facilitates patient management by a CCC or PCP, providing real-time access to a patient’s asthma control status, poor asthma control alerts, graphs/decision support, adherence to weekly e-AT use, and patient contact methods. Following the alert, the clinic proactively contacts patients/parents to identify and address asthma care issues and adjust treatments if needed using step therapy.

**Intensive e-AT intervention:** Intensive e-AT was developed to increase participant adherence with weekly use through additional motivational features (Figure 7), including a progress bar, which adds 25 points/participant completion of an assessment. At 100 points (~4 assessments per month), a pop-up message is generated that includes fireworks, a congratulatory message, and a notice that an incentive ($10 gift certificate) is being sent by mail. The incentive system resets to 0 after it reaches 100 points. The second motivational feature is the leader board, which allows participants to see adherence of the 5 best e-AT users, motivating them to increase their own adherence. Standard e-AT users were also sent the gift after 4 assessments per month but did not see the progress bar, leader board, fireworks, or congratulatory message. Yet, the graph about the child’s asthma status, recommendations about management, and clinic dashboard were similar in both standard and intensive interventions.
Figure 3. e-AT web version

Figure 4. e-AT mobile web version
Figure 5. User interface (dynamic run chart): Standard e-AT intervention

Figure 6. Care coordinator dashboard
D.5. Follow-up

**Recruitment and consent procedures:** Planned recruitment/enrollment was to occur from June 1, 2013, to June 30, 2015, but it was delayed by the study design change and PCORI approval process. We therefore extended recruitment to December 31, 2015 (with follow-up data collection through December 31, 2016) to reach the updated sample size of 315 participant dyads. Eligible participants with persistent asthma (using NIH criteria) were consented (informed consent or parental permission plus assent), allocated to a study arm (early vs late clinics, and standard vs intensive e-AT), and provided asthma education/instructions on how to access and use the e-AT, including a temporary user name/password to be modified upon first login, allowing full e-AT access.
**Randomization procedure:** Across the 11 enrolled clinics, including 6 early clinics (3 large [>100 potential enrollees] and 3 small [≤100]) and 5 late starting clinics (3 large and 2 small), participants were cluster-randomized by computer algorithm on September 17, 2014, to the standard or intensive e-AT intervention (Figure 2).

D.6. Study Outcomes

**Primary outcomes:** QOL scores were collected using the Integrated Therapeutics Group Child Asthma Short Form (ITG-CASF). QOL scores range from 1 (poor QOL) to 100 (better QOL).

**Secondary outcomes:** Asthma control (scores ranging from 5 [poorest asthma control] to 25 [optimal asthma control]), interrupted/missed school days (number), parent satisfaction (scores reported at 1 = very dissatisfied, 2 = dissatisfied, 3 = neutral, 4 = satisfied, and 5 = very satisfied), parent interrupted/missed work days (number), oral steroid use (number), and ED/hospital admissions (number).

D.7. Data Collection and Sources

At enrollment, parents completed surveys addressing demographic, socioeconomic, and behavioral factors; parent satisfaction; and education level (replaced health literacy). A technology factor survey also included 2 open-ended questions assessing barriers/facilitators of parent participation. Baseline surveys were collected at the time of enrollment on paper, but follow-up surveys were collected online using REDCap (Research Electronic Data Capture). Outcomes data, including ED/hospital admissions—using ICD-9 and ICD-10 codes and oral corticosteroid use, 1 year pre- and 1 year post-e-AT initiation—were collected using the Intermountain Healthcare EDW, an integrated database linking administrative and clinical data from Intermountain hospitals and clinics. The EDW was also used to collect patient demographics (age, gender, race, and insurance) and to create a matched control group. **Table**
lists data elements, validated survey instruments and references, data sources, and frequency of data collection.

**Table 1. Timeline of Data Collection and Survey Instrument and Data Collection Source**

<table>
<thead>
<tr>
<th>Study Variables</th>
<th>Data Source</th>
<th>Baseline</th>
<th>Month 3</th>
<th>Month 6</th>
<th>Month 12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographic survey</td>
<td>Structured questions (Appendix)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insurance coverage</td>
<td>Structured questions (with the demographic survey)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Socioeconomic status (parents)</td>
<td>Structured questions (with the demographic survey)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Behavioral (parents)</td>
<td>Structured questions (knowledge/understanding, self-efficacy, attitudes/beliefs, family support, peer support, autonomy/control) (see Appendix)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Technology factors (parents)</td>
<td>Structured questions (eg, usefulness, information satisfaction, ease of use, completeness, format, accuracy, currency, information quality, reliability, accessibility, timeliness)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quality of life (child)</td>
<td>Integrated Therapeutics Group Child Asthma Short Form&lt;sup&gt;51,52&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Health literacy (parents)</td>
<td>Test of Functional Health Literacy in Adults&lt;sup&gt;54&lt;/sup&gt;</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parent satisfaction with care</td>
<td>Modified version of patient satisfaction survey validated by Varmi et al&lt;sup&gt;55&lt;/sup&gt;</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Asthma control</td>
<td>e-AT assessment</td>
<td>Weekly during the study period</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Frequency of e-AT use</td>
<td>e-AT logs</td>
<td>Weekly during the study period</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interrupted/missed school days (child)</td>
<td>Weekly assessment through the e-AT</td>
<td>Weekly during the study period</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interrupted/missed work days (Parents)</td>
<td>Weekly assessment through the e-AT</td>
<td>Weekly during the study period</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ED and hospital admission (child)</td>
<td>Electronic Data Warehouse&lt;sup&gt;53&lt;/sup&gt;</td>
<td>End of the study (any time it happens)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Use oral steroids (child)</td>
<td>Electronic Data Warehouse</td>
<td>End of the study (any time it happens)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> Baseline surveys were completed in clinics at the time of enrollment, and follow-up surveys were collected using mail or REDCap.
**Follow-up and retention strategies**: We used multiple strategies to increase retention, including obtaining contact information of at least 2 family members at enrollment, providing incentive, mailing thank you cards, and confirming contact information at follow-up assessments. Patients who stopped using the e-AT were contacted by the research coordinator and/or CCC to motivate ongoing adherence or identify and document reasons for withdrawal or loss to follow-up (triggered by ~3 months of inactivity).

### D.8. Statistical Analysis

We used SAS 9.4 statistical software (https://www.sas.com/en_us/software/sas9.html) to conduct all analyses. The new design allowed randomized comparisons of 2 levels of e-AT intensity, but not e-AT effectiveness vs usual care. Consequently, we included 2 general categories of analyses:

1. **Randomized comparisons of standard vs intensive e-AT, comparing QOL and secondary outcomes.**

2. **Four nonrandomized analyses to assess the e-AT effectiveness compared with usual care.**
   
a. The first analysis assessed longitudinal change within-patient (both standard and intensive e-AT users) in outcomes (QOL, satisfaction, asthma control, interrupted/missed school days, and interrupted/missed work days) compared between baseline (prior to e-AT initiation) and follow-up assessments while using the e-AT.
   
b. The second analysis (early vs late starting clinics) or clinic-level analysis compared oral steroid use and hospital/ED admissions between enrolled subjects in clinics that started the e-AT early vs subjects in clinics that started the e-AT late (see also D.9.3.3).
   
c. The third analysis (early vs late starting patients) or patient-level analysis involved both standard and intensive e-AT and compared oral steroid use and ED/hospital admissions between enrolled subjects that started the e-AT in the first year vs those that started the e-AT
in the second year, during the 1-year period prior to their e-AT start dates (serving as usual care
period) when late starting subjects were not using the e-AT (see also D.9.3.4).

d. The last analysis (limited to ED/hospital admissions and oral steroid use) compared
subjects in the e-AT (standard and intensive) groups vs nonrandomized matched controls or
subjects with persistent asthma from clinics that did not participate in the e-AT study.

**Original power calculation:** The original calculation for the primary (QOL) outcome
assumed 480 subjects would be enrolled, with 400 completing 12 months of follow-up,
distributed across clinics, and assumed a standard deviation (SD) of 20 points for QOL with an
intraclass correlation (ICC) of 0.015 to account for potential clustering of QOL scores by clinics.
Under these assumptions, the design would have provided 80% power with a 1-sided \( \alpha \) of 0.05
to detect a difference in the mean QOL score of 6.3 points between the treatment groups,
representing a relatively small treatment effect of about 31.5% of 1 SD in QOL score. This
calculation was conservative in 3 aspects: (1) the detectable effect of 31.5% of 1 SD was small,
(2) the power calculation did not account for added precision resulting from having multiple
QOL assessments during the follow-up period, and (3) the power calculation did not account for
likely gains in power resulting from statistical adjustment for the baseline QOL score. Thus,
while there was considerable uncertainty in the projected ICC, the design left some margin of
error in the power calculation that would have mitigated the effects of a smaller-than-projected
enrollment.

**Updated power calculation (June 2016):** The actual number of patients with 6-month
follow-up was 52 in the intensive e-AT and 233 in the standard e-AT intervention. Enrollment
was substantially imbalanced across sites, with \( \geq 20 \) patients randomized in 4 sites assigned to
the standard and 1 site on the intensive e-AT. Thus, the amount of data to estimate between-
site variation in QOL and other outcomes was very limited, making statistical inferences under
mixed models problematic. As a result, the primary analysis was modified to be a fixed-effects
analysis that would apply statistical inferences specifically to sites included in the study, with
the recognition that generalization of the study results beyond sites in this specific trial would
have to be based on subject-matter considerations rather than direct statistical inference.
Assuming an SD of 20 units, the sample sizes of 233 and 52 patients would provide 80% power with a 1-sided $\alpha = 0.05$ to detect a mean difference of 7.65 points (or 38% of 1 SD). If we further assumed the correlation between the baseline QOL score and the mean follow-up QOL score was 0.5 or greater, the minimum detectable effect size was reduced to 6.63 points (or 33% of 1 SD). In spite of the lower-than-planned sample size in the intensive e-AT group, these detectable effects were not substantially changed from the minimum detectable effects (MDE) we projected in September 2015. This reflects 2 factors. First, the impact of the imbalance between 233 and 52 subjects in the 2 groups was not as large as we expected at first glance, and the MDE with 233 in one group and 52 in the other group was just 29% greater than the MDE for an equal allocation of the 285 total patients to the 2 groups. Second, because we were now applying the statistical inferences specifically to the study sites under a fixed model instead of attempting more general inferences under a mixed model, it was no longer necessary to account for the design effect due to the facility-level ICC. In other words, the unbalanced randomization across sites has forced us to “lower the bar” and perform fixed-effects inference instead of using a mixed effects model, but the statistical power to reach these conclusions was not appreciably reduced.

**Final updated power calculation for fixed-effects analysis (October 2016):** The actual numbers of patients with at least 12-month follow-up was 49 in the high-intensive e-AT and 214 in the standard e-AT intervention. Enrollment was substantially imbalanced across sites, with ≥20 patients randomized in 4 sites assigned to the standard e-AT and 1 site (with >20 patients) on the intensive e-AT. As noted above, we therefore planned to perform both mixed and fixed-effects analyses. In addition, the analysis plan had to be modified to account for varying follow-up times for each patient after randomization. We assumed a cross-sectional SD of 20 units, and that at least 90% of the 214 and 49 patients in the standard and intensive e-AT groups would have a nonmissing QOL measurement at their final (12-month) planned follow-up QOL, and that baseline covariates would not be substantially imbalanced between clinics randomized to the intensive and standard e-AT. Under these assumptions, when the fixed-effects analysis was used, the study provided 80% power with a 1-sided $\alpha = 0.05$ to detect a mean difference of
8.33 points (or 42% of 1 SD). If we further assumed that the correlation between the baseline and the final follow-up QOL score was $\geq 0.5$, the MDE size was reduced to 7.21 points (or 36% of 1 SD).

D.9. OBJECTIVE 1: Assess the Effectiveness of the New Ambulatory Care Model

D.9.1. Descriptive Analyses: We summarized baseline characteristics and outcome measures at each follow-up, overall, and within each arm, using means, medians and ranges for continuous variables, and frequencies for categorical and ordinal variables. The balance of baseline measures across the 2 intervention arms were compared with robust variance estimates to account for clustering by clinic.

D.9.2. Randomized Comparisons Between Standard and Intensive e-AT Interventions: See Figure 2.

Data used: The first QOL and other outcomes obtained at enrollment were used as baseline values, reflecting patient outcomes under usual care (without e-AT exposure). When comparing both interventions, follow-up outcomes were restricted to postrandomization measurements. Measurements after baseline and prior to randomization were excluded so the analysis represents a true comparison of randomized groups.

Analyses of QOL: We used a linear fixed-effects (LFE) model to estimate the adjusted mean QOL score change at each postrandomization follow-up in the intensive and standard e-AT. Linear contrasts were used to compare mean QOL change at each follow-up between clinics assigned to intensive vs standard e-AT, each clinic weighted by the number of subjects contributing to the analysis at each assessment. An adjustment for the length of time between randomization and postrandomization QOL assessments was performed and an unstructured covariance model was used to account for serial correlation.

In addition, we used a linear mixed effects (LME) model to include a random effect for clinic to account for clinic clustering. An unstructured covariance model was used to account for
correlations of model residuals between measurements in the same patient. We based the primary comparison on estimated treatment effect at the final follow-up (12 months). To account in part for the small number of clinics providing substantive information concerning random-effects variance, we used restricted likelihood estimation with Kenward-Roger estimates for degrees of freedom.

**Secondary outcomes analyses:** We used linear (continuous data) or generalized linear (categorical/count data) fixed- or mixed-effects models (LFE/GLFE or LME/GLME). Due to imbalanced/small patient numbers at some clinics, GLME modeling was limited. We relied on GLFE to compare categorical outcomes or count data between intervention groups. Analyses were also restricted to assessments occurring postrandomization.

1. **Parent satisfaction.** As in QOL, we attempted to fit LME models to provide generalizability inferences beyond the study clinics and LFE models to provide inferences to participating clinics. The models included terms to adjust for the length of time between randomization and postrandomization follow-up assessments.

2. **Asthma control.** Asthma control was analyzed similarly in random patient effects models using ACT scores. We compared the proportion of assessments with good control (score 19-25) vs poor control (scores 5-18).

3. **ED/hospital admissions and oral steroid use.** The GLFE models, adjusting for baseline imbalances, for these outcomes used negative binomial distribution, with offsets for postrandomization follow-up time and adjustment terms to account for proportion of assessments occurring postrandomization, but fitted separate mean event rates for each clinic. The treatment effects were estimated by comparing weighted averages of the estimated event rates between clinics assigned to intensive vs standard e-AT. GLME models were also fitted for negative binomial outcomes with logarithmic link functions and random clinic effects to outcome events occurring postrandomization. Robust sandwich estimates of standard errors were used for statistical inference.
4. **Interrupted or missed school and work days.** We compared proportion of school and work days interrupted or missed during 3-month intervals prior to the final 12-month follow-up assessment and used the negative binomial distribution. Analyses used GLME and GLFE models as in ED/hospitalizations and oral steroid use, except events were ascertained only during the 3-month period prior to the final 12-month assessment, and the offset term was defined as the number of potential school or work days for which absence was evaluated.

**D.9.3. Five Nonrandomized Comparisons Between e-AT Interventions vs Usual Care**

**D.9.3.1. Longitudinal within-subject analyses:** We determined mean change (from baseline to follow-up assessments) of QOL, asthma control, satisfaction, and rates of interrupted/missed school/work days.

1. **QOL.** We fitted an LFE repeated measure model for repeated QOL measurements, with study clinic, time (as a categorical factor), and clinic by time interaction terms used in the model as fixed effects, with a common unstructured covariance matrix to account for correlations in QOL measurements in the same patient. Linear contrasts were used to estimate mean change in QOL across all clinics (assigned to both intensive and standard e-AT) between the baseline assessment and each of the 3 follow-up assessments individually.

2. **Asthma control.** We used random patient effects models using ACT scores as a continuous and binary outcome (19-25 vs 5-18). Since ACT scores were measured at irregular times and repeated multiple times for some patients, we used a compound symmetry working covariance to avoid estimating too many nuisance variance parameters. In analyses, similar to QOL, we provided mean changes from baseline to first, second, third, and fourth quarter, with initial tests treated as baseline values. We also related ACT scores to overall e-AT adherence by adding as a covariate cumulative proportion of weeks with e-AT use prior to and including that week (dichotomized as
60% + vs 60% –) during follow-up period. We reported estimated mean changes from baseline to each quarter for compliers and noncompliers, and contrasts between compliers and noncompliers.

3. **Parent satisfaction.** Analyses similar to QOL, were repeated for satisfaction score used as a continuous outcome using LFE model. We also dichotomized satisfaction score as satisfactory ( >3) vs unsatisfactory (≤ 3). GLFE patient effects model with binomial distribution and logit link were used to fit this binary outcome.

4. **Interrupted/missed school/work days, ED/hospital admissions, oral steroid use.** We assessed changes in rates of ED/hospital admissions, oral steroid use, interrupted/missed school days, and interrupted/missed work days, between baselines and 3-, 6-, and 12-month follow-up assessments, applying a generalized estimating equation (GEE) with robust standard errors and compound symmetry working covariance model under Poisson or negative binomial model. The model estimated the overall rate ratios for the outcomes between baseline and the 3 follow-up assessments.

5. **Subgroups analyses of QOL and asthma control for Hispanic/Latino and Medicaid children.** Analyses were similar to QOL and asthma control described above but restricted to the subgroups. The goal was to assess the e-AT impact on disadvantageous populations who experience asthma disparities. Most Hispanic patients in Utah are of low-income families and face multiple barriers to care.

**D.9.3.2. Comparisons of ED/Hospital Admissions and Oral Steroids Used Between the Year Following and the Year Prior to Each Patient’s Enrollment Visit:** We used clustered negative binomial regression (to account for matching of the preperiods and postperiods within each subject) and included offsets to account for the duration of time each patient was evaluated for hospital/ED admissions and oral steroids used during the pre e-AT and post-e-AT periods. The analysis compared the baseline period with the full follow-up period for each subject, irrespective of whether a portion of the follow-up period was under the intensive or standard e-AT intervention.
D.9.3.3. Comparison of ED/Hospital Admissions and Oral Steroid Use Between Patients Enrolled in the 6 Early Starting Clinics vs Patients Enrolled in the 5 Late Starting Clinics, During Months 1 to 3 Delay: Patients enrolled in the early starting clinics (clinics that started on January 1, 2014) were already using the standard e-AT while those enrolled in the late starting clinics (clinics that started on April 1, 2014) were receiving usual care during the 3-month delay period (between January 1, 2014, and March 31, 2014), used as usual care period. Effects were compared during the delay period using weighted averages of estimated event rates between early vs late starting clinics. We applied GLME models for negative binomial with logarithmic link functions and random site effects to compare the rates of hospital/ED visits and oral steroid use occurring during the delay period. The outcome model included offsets to account for each subject’s duration of follow-up during the period of analysis.

D.9.3.4. Comparison of ED/Hospital Admissions and Oral Steroid Use 1 Year Post-e-AT Initiation for Patients Who Started the Intervention Early vs During a 1-year Period Prior to Starting the e-AT for Those Who Started the e-AT Later: Analyses (patient level) compared rates of ED/hospital admissions and oral steroid use during 1-year post-e-AT initiation for those who were enrolled early (between January 2014 to December 2014) or in the first year (early starting patients), while using the e-AT (intervention period), to rates during a 1-year period prior to enrollment of patients who were enrolled late (between January 2015 to December 2015) or in the second year (late starting patients), while not using the e-AT (usual care period).

Rationale: Subjects in the control group (late patients were receiving usual care) later met study eligibility criteria, and their pre-enrollment usual care time periods (including change in seasons) coincided with the post-enrollment time periods of those who enrolled early, limiting the confounding effects of secular trends in asthma care. A GLME model was used with a negative binomial distribution, logarithmic link function, and random site effects to compare the rates between the 2 groups.
D.9.3.5. Nonrandomized Comparison of Outcomes Between Patients From Randomized Clinics While Using the e-AT vs a Nonrandomized Matched Control Cohort of Children With Persistent Asthma From Nonparticipating Clinics: The above analyses allowed comparisons between different times, leading to possible secular trends bias. The requirement that the control period ends prior to e-AT initiation and that the intervention period starts after index clinic visits was also a source of asymmetry that could lead to bias. To address these potential biases, we added another nonrandomized analysis, comparing outcomes between patients from randomized clinics while using the e-AT to a matched control group of patients from nonparticipating clinics. This analysis compared the e-AT with a control group not exposed to the e-AT, using concurrent evaluation periods; and addition of new clinics also increased statistical power.

Matching variables: Randomized patients (2 controls per 1 treated patient) were matched by age, sex, clinic location, asthma severity (persistent, based on controller use with at least 2 prescriptions within the past year), clinic visit dates for controls within ± 2 months of enrollment dates of intervention patients, and clinic visit types (asthma vs non-asthma–related).

Data elements: We pulled the following data from the Intermountain EDW (both intervention groups and matched controls): unique patient identifier, account number, birthdate/age at clinic visit, clinic visit date, sex, insurance, clinic name, diagnosis (using ICD-9 and ICD-10 codes), controller prescription and steroid use (using national drug codes), and ED/hospital admissions. Matched controls were drawn from 42 nonparticipating clinics within the IH system located in Salt Lake City and Utah County, where randomized clinics are located.

Statistical analysis: We compared ED/hospital admissions and steroid use rates during 12-month follow-up period between patients on e-AT vs matched controls using GLME with a negative binomial outcome, logarithmic link, and random site effects. The model used each
matching variable and prior ED/hospital admission and steroids use rates in the preceding 12 months as covariates. The basic model provided overall comparisons between e-AT intervention and controls, irrespective of the intervention used (standard or intensive e-AT).


We assessed the e-AT (standard and intensive interventions) effectiveness in different parent subgroups (eg, high vs low education, private vs Medicaid insurance). Health literacy was replaced by education because of lack of time by CCC and difficulty of data collection during clinic visits.

For ED/hospitalization admissions, we used Cox regression to relate the risk of first hospital/ED admission to the cumulative proportion of e-AT use (numbers of weeks) prior to that admission in a 3-month window, along with indicator variables for low education and Medicaid insurance at baseline, and an interaction term between indicator variables. The baseline hazard function was stratified by clinic site. We also assessed the dose-response relationship between risk of hospital/ED admissions and the cumulative proportion of e-AT use (categorized), comparing patients with vs without low education and Medicaid vs private insurance subgroups.

For asthma control, we applied GEE for binary ACT scores (19-25 vs 5-18) with logistic link function and robust standard errors under an independence working covariance model to relate the odds of good control during a given week to the cumulative proportion of e-AT use (in a 3-month window) prior to that week, using the same sets of covariates (plus clinic site as a covariate rather than a stratification factor) and interaction terms to compare dose-response relationships of the odds of good asthma control with prior cumulative proportion of e-AT use between low vs high education and Medicaid vs private insurance.
For QOL, we used GEE by applying a normal outcome model with an identity link function, and QOL measurements at 3, 6, and 12 months each related to the cumulative proportion of e-AT use prior to the week of QOL measurement, using the above covariates and interaction terms. We also compared dose-response relationships of mean QOL with prior cumulative proportion of e-AT use across the 2 subgroups.

D.11. OBJECTIVE 3: Determine Factors Associated With Sustained Parent Participation in Asthma Self-management

We defined a dichotomous outcome for each month as “frequent” (if ≥ 3 weekly assessments recorded/month) or “nonfrequent” e-AT users otherwise. We used a logistic regression model to relate the odds of frequent e-AT use to sets of predictor variables after adjusting for clinic (categorical factor), with the following sequence:

(1) We applied subject matter considerations to define baseline predictors, including demographic (parent age, sex, and race/ethnicity), socioeconomic (marital status, highest education completed, household income, number of children in household, and primary language spoken), behavioral, and technology factors, and subdivided predictors into modifiable and nonmodifiable.

(2) We examined correlation matrices, variance inflation factors, and contingency tables to identify any collinear factors and reduce the list of predictors, if needed.

(3) We examined the association of e-AT use frequency with each predictor by fitting separate GEE for each predictor, with clinic used as a categorical covariate.

(4) We introduced the assignment to the intensive e-AT as a time-dependent covariate in each GEE model. We examined interaction terms between baseline predictors and treatment assignment to determine if the association of sustained participation and predictor variables differs in time period when the intensive e-AT was applied vs time period when it was not applied.
(5) We used multivariable GEE regressions to relate frequent use to each individual modifiable risk factor after adjustment for nonmodifiable factors, the time-dependent intensive e-AT indicator variable, and clinic as covariates.

D.12. Strategies for Handling Missing Data

Analyses described above were all applied to all available data, allowing all nonmissing variables to be included regardless of whether measurements were missing at a time point, as missing data seemed to occur at random. In general, analyses using the mixed effects models utilize likelihood-based statistical inference and remain unbiased so long as data are missing at random (MAR). Also, analyses using GEE remain nearly unbiased as long as data are missing completely at random (MCAR), making use of all nonmissing measurements of variables in the model, including baseline covariates.

D.13. Conduct of the Study

All changes to the original protocol, including reasons for changes, are described in previous sections of this report. Any changes that occurred after the study start date were documented in the study protocol. We obtained PCORI and IRB approvals prior to implementation of the study and subsequent changes.
RESULTS

E.1. OBJECTIVE 1: Assess the Effectiveness of the New Ambulatory Care Model

Of the 11 participating clinics, 2 had only 1 patient enrolled. These 2 clinics (and the 2 patients) were excluded from all analyses. Of the 325 children/parents enrolled, 318 (97.2%) completed their baseline surveys and were included in descriptive analysis of baseline characteristics. Figure 8 (CONSORT diagram) shows the study population at different times. The dropout rates at 3, 6, and 12 months were similar between the 2 groups, including 10.0%, 12.7%, and 20.9%, respectively, for the standard e-AT intervention, and 13.3%, 13.3%, and 20.0%, respectively, for the intensive intervention.²

E.1.1. Randomized Comparisons Between Standard and Intensive e-AT Interventions

Of the 318 children, 261 (82%) received the standard e-AT intervention and 57 (18%) the intensive e-AT intervention. Table 2 provides baseline characteristic distribution of the study population.

E.1.1.1. Primary outcome (QOL): Overall baseline average QOL scores were 77.5 (95% CI, 71.1-83.8) points for the standard e-AT and 79.2 (95% CI, 72.5-85.9) for the intensive e-AT (P = 0.713). There was a significant QOL improvement over baseline at 3, 6, and 12 months (P < 0.001) following implementation of the standard and intensive e-AT interventions individually and overall (Tables 3 and 4). However, when compared together there was no difference (P = 0.961) between the 2 interventions. Figure 9 shows change from baseline (x-axis) at different follow-up times, with highest QOL increase occurring at 3 and 12 months, for both interventions. Overall, both interventions were effective in improving QOL over time. Although participants on the standard e-AT intervention tended to have highest QOL scores at all follow-

² The 4-clinicaltrials.gov tables (patient flow, baseline characteristics, outcomes and statistical analysis, and adverse events) are available at clinicaltrials.gov.
ups, no statistical difference were found between them. Therefore, additional motivational mechanisms built within the intensive e-AT intervention to improve user adherence did not make any differences in outcomes.

**E.1.1.2. Asthma control:** Overall, asthma control scores increased significantly \((P < 0.001)\) in both intensive and standard e-AT interventions individually and overall (**Figure 10** and **Tables 5 and 6**), across all follow-up quarters. However, increases in asthma control among participants on the intensive e-AT tended to be lower than increases seen in those on standard e-AT. However, when compared, there was no difference \((P = 0.926)\) in asthma control between the 2 groups.
Figure 8. CONSORT diagram
Table 2. Baseline Characteristics of Children Who Receive Intensive vs Standard e-AT Interventions

<table>
<thead>
<tr>
<th>Baseline Patient Characteristics, N (%)</th>
<th>Total</th>
<th>Intensive e-AT</th>
<th>Standard e-AT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total N</td>
<td>318</td>
<td>57 (18)</td>
<td>261 (82)</td>
</tr>
<tr>
<td><strong>PATIENT DEMOGRAPHICS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (mean [SD])</td>
<td>7.95 (3.96)</td>
<td>7.18 (3.78)</td>
<td>8.12 (3.99)</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>127 (40)</td>
<td>23 (40)</td>
<td>104 (40)</td>
</tr>
<tr>
<td>Male</td>
<td>191 (60)</td>
<td>34 (60)</td>
<td>157 (60)</td>
</tr>
<tr>
<td>Insurance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medicaid</td>
<td>51 (16)</td>
<td>11 (19)</td>
<td>40 (15)</td>
</tr>
<tr>
<td>Private</td>
<td>203 (64)</td>
<td>28 (49)</td>
<td>175 (67)</td>
</tr>
<tr>
<td>Self-pay</td>
<td>4 (1)</td>
<td>--</td>
<td>4 (2)</td>
</tr>
<tr>
<td>Unknown</td>
<td>60 (19)</td>
<td>18 (32)</td>
<td>42 (16)</td>
</tr>
<tr>
<td>Ethnicity (missing N = 15)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic, Latino</td>
<td>40 (13)</td>
<td>3 (6)</td>
<td>37 (14.6)</td>
</tr>
<tr>
<td>Not Hispanic or Latino</td>
<td>260 (86)</td>
<td>46 (94)</td>
<td>214 (84.3)</td>
</tr>
<tr>
<td>Unavailable</td>
<td>1 (0.33)</td>
<td>--</td>
<td>1 (0.4)</td>
</tr>
<tr>
<td>Declined to answer</td>
<td>2 (0.66)</td>
<td>--</td>
<td>2 (0.8)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic</td>
<td>36 (11)</td>
<td>2 (4)</td>
<td>34 (13)</td>
</tr>
<tr>
<td>Other</td>
<td>25 (8)</td>
<td>3 (5)</td>
<td>22 (8)</td>
</tr>
<tr>
<td>Unknown</td>
<td>14 (4)</td>
<td>5 (9)</td>
<td>9 (3)</td>
</tr>
<tr>
<td>White</td>
<td>243 (76)</td>
<td>47 (82)</td>
<td>196 (75)</td>
</tr>
</tbody>
</table>
Table 3. Summary of QOL by Clinic and by Timeline

<table>
<thead>
<tr>
<th></th>
<th>N</th>
<th>MEAN</th>
<th>SD</th>
<th>MINIMUM</th>
<th>MAXIMUM</th>
</tr>
</thead>
<tbody>
<tr>
<td>OVERALL</td>
<td>840</td>
<td>85.85</td>
<td>13.32</td>
<td>20.00</td>
<td>100.00</td>
</tr>
<tr>
<td>CLINIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BRYNER</td>
<td>27</td>
<td>80.96</td>
<td>14.74</td>
<td>56.00</td>
<td>100.00</td>
</tr>
<tr>
<td>HILLCREST</td>
<td>86</td>
<td>79.79</td>
<td>15.24</td>
<td>40.00</td>
<td>100.00</td>
</tr>
<tr>
<td>HOLLADAY</td>
<td>327</td>
<td>89.57</td>
<td>11.33</td>
<td>20.00</td>
<td>100.00</td>
</tr>
<tr>
<td>JOHNSON</td>
<td>57</td>
<td>87.30</td>
<td>9.77</td>
<td>60.00</td>
<td>100.00</td>
</tr>
<tr>
<td>MEMORIAL</td>
<td>195</td>
<td>83.54</td>
<td>14.10</td>
<td>42.00</td>
<td>100.00</td>
</tr>
<tr>
<td>REDROCK</td>
<td>15</td>
<td>95.20</td>
<td>7.28</td>
<td>80.00</td>
<td>100.00</td>
</tr>
<tr>
<td>SANDY</td>
<td>13</td>
<td>81.69</td>
<td>10.95</td>
<td>62.00</td>
<td>100.00</td>
</tr>
<tr>
<td>SOUTHRIDGE</td>
<td>23</td>
<td>77.39</td>
<td>15.19</td>
<td>52.00</td>
<td>100.00</td>
</tr>
<tr>
<td>UVPROVO</td>
<td>97</td>
<td>84.98</td>
<td>13.57</td>
<td>42.00</td>
<td>100.00</td>
</tr>
<tr>
<td>TIMELINE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BASELINE</td>
<td>318</td>
<td>79.07</td>
<td>14.20</td>
<td>40.00</td>
<td>100.00</td>
</tr>
<tr>
<td>3 MONTHS</td>
<td>132</td>
<td>89.70</td>
<td>10.85</td>
<td>46.00</td>
<td>100.00</td>
</tr>
<tr>
<td>6 MONTHS</td>
<td>183</td>
<td>89.40</td>
<td>11.54</td>
<td>20.00</td>
<td>100.00</td>
</tr>
<tr>
<td>12 MONTHS</td>
<td>207</td>
<td>90.70</td>
<td>10.22</td>
<td>42.00</td>
<td>100.00</td>
</tr>
</tbody>
</table>
Table 4. QOL/Intensive vs Standard e-AT Interventions at Different Follow-ups (Fixed-effects Model)

<table>
<thead>
<tr>
<th>LABEL</th>
<th>ADJUSTED MEAN CHANGE</th>
<th>95% CI LOWER</th>
<th>95% CI UPPER</th>
<th>P VALUE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intensive 3 months (m) vs baseline</td>
<td>7.6455</td>
<td>2.6703</td>
<td>12.6206</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Intensive 6 m vs baseline</td>
<td>5.7779</td>
<td>1.9664</td>
<td>9.5893</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Intensive 12 m vs baseline</td>
<td>9.2956</td>
<td>5.7624</td>
<td>12.8289</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Standard 3 m vs baseline</td>
<td>8.5491</td>
<td>6.6455</td>
<td>10.4527</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Standard 6 m vs baseline</td>
<td>8.3655</td>
<td>6.6866</td>
<td>10.0444</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Standard 12 m vs baseline</td>
<td>9.3911</td>
<td>7.8932</td>
<td>10.8890</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Intensive vs standard and 3 m vs baseline</td>
<td>-0.9037</td>
<td>-6.2306</td>
<td>4.4233</td>
<td>0.7395</td>
</tr>
<tr>
<td>Intensive vs standard and 6 m vs baseline</td>
<td>-2.5876</td>
<td>-6.7525</td>
<td>1.5772</td>
<td>0.2233</td>
</tr>
<tr>
<td>Intensive vs standard and 12 m vs baseline</td>
<td>-0.9037</td>
<td>-3.9331</td>
<td>3.7422</td>
<td>0.9611</td>
</tr>
</tbody>
</table>

Figure 9. Least squares means of change (x-axis) in QOL: Intensive vs standard
Figure 10. Least squares means of change (x-axis) in asthma control scores: Intensive vs standard
Table 5. Summary of Asthma Control Score per Quarter and per Clinic

<table>
<thead>
<tr>
<th></th>
<th>N</th>
<th>MEAN</th>
<th>SD</th>
<th>MINIMUM</th>
<th>MAXIMUM</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>OVERALL</strong></td>
<td>8965</td>
<td>22.57</td>
<td>3.19</td>
<td>5</td>
<td>25</td>
</tr>
<tr>
<td><strong>TIMELINE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BASELINE</td>
<td>311</td>
<td>18.85</td>
<td>5.49</td>
<td>5</td>
<td>25</td>
</tr>
<tr>
<td>QUARTER 1</td>
<td>1529</td>
<td>22.19</td>
<td>3.2</td>
<td>5</td>
<td>25</td>
</tr>
<tr>
<td>QUARTER 2</td>
<td>2049</td>
<td>22.66</td>
<td>3.02</td>
<td>6</td>
<td>25</td>
</tr>
<tr>
<td>QUARTER 3</td>
<td>2521</td>
<td>22.77</td>
<td>3.03</td>
<td>5</td>
<td>25</td>
</tr>
<tr>
<td>QUARTER 4</td>
<td>2555</td>
<td>22.97</td>
<td>2.76</td>
<td>6</td>
<td>25</td>
</tr>
<tr>
<td><strong>CLINIC</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BRYNER</td>
<td>345</td>
<td>21.65</td>
<td>4.25</td>
<td>6</td>
<td>25</td>
</tr>
<tr>
<td>HILLCREST</td>
<td>832</td>
<td>22.03</td>
<td>3.27</td>
<td>5</td>
<td>25</td>
</tr>
<tr>
<td>HOLLADAY</td>
<td>3850</td>
<td>23.06</td>
<td>2.78</td>
<td>5</td>
<td>25</td>
</tr>
<tr>
<td>JOHNSON</td>
<td>510</td>
<td>22.45</td>
<td>3.17</td>
<td>6</td>
<td>25</td>
</tr>
<tr>
<td>MEMORIAL</td>
<td>2093</td>
<td>22.32</td>
<td>3.41</td>
<td>5</td>
<td>25</td>
</tr>
<tr>
<td>REDROCK</td>
<td>158</td>
<td>22.33</td>
<td>2.65</td>
<td>10</td>
<td>25</td>
</tr>
<tr>
<td>SANDY</td>
<td>53</td>
<td>21.25</td>
<td>5.04</td>
<td>5</td>
<td>25</td>
</tr>
<tr>
<td>SOUTHRIDGE</td>
<td>140</td>
<td>21.44</td>
<td>4.42</td>
<td>5</td>
<td>25</td>
</tr>
<tr>
<td>UVPROVO</td>
<td>984</td>
<td>22.3</td>
<td>3.2</td>
<td>5</td>
<td>25</td>
</tr>
</tbody>
</table>
Table 6. Asthma Control/Intensive vs Standard Interventions at Different Follow-up (Fixed Effect)

<table>
<thead>
<tr>
<th>LABEL</th>
<th>ADJUSTED MEAN CHANGE</th>
<th>SE</th>
<th>95% CI LOWER</th>
<th>95% CI UPPER</th>
<th>P VALUE</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTENSIVE QUARTER (QTR) 1 VS BASELINE</td>
<td>1.7814</td>
<td>0.3492</td>
<td>1.0969</td>
<td>2.4659</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Intensive qtr 2 vs baseline</td>
<td>2.1825</td>
<td>0.2980</td>
<td>1.5983</td>
<td>2.7667</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Intensive qtr 3 vs baseline</td>
<td>2.1753</td>
<td>0.2268</td>
<td>1.7307</td>
<td>2.6198</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Intensive qtr 4 vs baseline</td>
<td>3.3039</td>
<td>0.2151</td>
<td>2.8822</td>
<td>3.7255</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Standard qtr 1 vs baseline</td>
<td>2.5517</td>
<td>0.1196</td>
<td>2.3172</td>
<td>2.7862</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Standard qtr 2 vs baseline</td>
<td>3.0905</td>
<td>0.1022</td>
<td>2.8903</td>
<td>3.2908</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Standard qtr 3 vs baseline</td>
<td>3.2606</td>
<td>0.0949</td>
<td>3.0746</td>
<td>3.4466</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Standard qtr 4 vs baseline</td>
<td>3.3260</td>
<td>0.0988</td>
<td>3.1323</td>
<td>3.5196</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Intensive vs standard and qtr 1 vs baseline</td>
<td>-0.7703</td>
<td>0.3691</td>
<td>-1.4938</td>
<td>-0.0467</td>
<td>0.0369</td>
</tr>
<tr>
<td>Intensive vs standard and qtr 2 vs baseline</td>
<td>-0.9080</td>
<td>0.3151</td>
<td>-1.5256</td>
<td>-0.2905</td>
<td>0.0040</td>
</tr>
<tr>
<td>Intensive vs standard and qtr 3 vs baseline</td>
<td>-1.0854</td>
<td>0.2459</td>
<td>-1.5673</td>
<td>-0.6034</td>
<td>0.0000</td>
</tr>
<tr>
<td>Intensive vs standard and qtr 4 vs baseline</td>
<td>-0.0221</td>
<td>0.2367</td>
<td>-0.4861</td>
<td>0.4419</td>
<td>0.9257</td>
</tr>
</tbody>
</table>

**E.1.1.3. Interrupted/missed school days:** Similar to QOL and asthma control, number of interrupted/missed school days were reduced significantly ($P < 0.001$) across all follow-ups (month) in both intensive and standard e-AT interventions individually and overall (Figure 11). Also, overall reduction in number of interrupted/missed school days among participants on the intensive e-AT tended to be lower (especially at 3 and 6 months) than reductions seen in patients on standard e-AT (Table 7). Yet, when compared, there was no difference ($P = 0.493$) in asthma scores between the 2 intervention groups.
Figure 11. Least squares means of change (x-axis) in interrupted/missed school days: Intensive vs standard
Table 7. Interrupted/Missed School Days/Intensive vs Standard Interventions Across Follow-ups (Fixed Effect)

<table>
<thead>
<tr>
<th>Label</th>
<th>Adjusted Rate Ratio</th>
<th>95% CI Lower</th>
<th>95% CI Upper</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intensive 3 months (m) vs baseline</td>
<td>1.0240</td>
<td>0.4874</td>
<td>2.1512</td>
<td>0.9500</td>
</tr>
<tr>
<td>Intensive 6 m vs baseline</td>
<td>0.7948</td>
<td>0.4546</td>
<td>1.3898</td>
<td>0.4206</td>
</tr>
<tr>
<td>Intensive 12 m vs baseline</td>
<td>0.3685</td>
<td>0.2225</td>
<td>0.6103</td>
<td>0.0001</td>
</tr>
<tr>
<td>Standard 3 m vs baseline</td>
<td>0.6009</td>
<td>0.4027</td>
<td>0.8967</td>
<td>0.0126</td>
</tr>
<tr>
<td>Standard 6 m vs baseline</td>
<td>0.3901</td>
<td>0.2649</td>
<td>0.5744</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Standard 12 m vs baseline</td>
<td>0.4645</td>
<td>0.3029</td>
<td>0.7124</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Intensive vs standard and 3 m vs baseline</td>
<td>1.7041</td>
<td>0.7332</td>
<td>3.9607</td>
<td>0.2154</td>
</tr>
<tr>
<td>Intensive vs standard and 6 m vs baseline</td>
<td>2.0376</td>
<td>1.0326</td>
<td>4.0207</td>
<td>0.0401</td>
</tr>
<tr>
<td>Intensive vs standard and 12 m vs baseline</td>
<td>0.7934</td>
<td>0.4095</td>
<td>1.5370</td>
<td>0.4927</td>
</tr>
</tbody>
</table>

**E.1.1.4. Interrupted/missed work days:** Fixed-effects analysis showed no change in the number of interrupted/missed work days across all follow-up periods for the intensive e-AT, but there was a significant ($P < 0.001$) reduction in standard e-AT overall and at 3, 6, and 12 months. Although those patients receiving the intensive intervention tended to have fewer interrupted/missed work days, there was no difference ($P = 0.119$, except at 6 months) between intensive and standard e-AT interventions (**Figure 12 and Table 8**).
Figure 12. Least squares means of change (x-axis) in interrupted/missed work days: Intensive vs standard
Table 8. Interrupted/Missed Work Days/Intensive vs Standard Interventions Across Follow-ups (Fixed Effect)

<table>
<thead>
<tr>
<th>Label</th>
<th>Adjusted Rate Ratio</th>
<th>95% CI Lower</th>
<th>95% CI Upper</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intensive 3 months (m) vs baseline</td>
<td>0.6862</td>
<td>0.1207</td>
<td>3.9016</td>
<td>0.6711</td>
</tr>
<tr>
<td>Intensive 6 m vs baseline</td>
<td>0.7394</td>
<td>0.3639</td>
<td>1.5020</td>
<td>0.4037</td>
</tr>
<tr>
<td>Intensive 12 m vs baseline</td>
<td>0.7477</td>
<td>0.3600</td>
<td>1.5531</td>
<td>0.4357</td>
</tr>
<tr>
<td>Standard 3 m vs baseline</td>
<td>0.3543</td>
<td>0.1940</td>
<td>0.6472</td>
<td>0.0007</td>
</tr>
<tr>
<td>Standard 6 m vs baseline</td>
<td>0.1651</td>
<td>0.0859</td>
<td>0.3173</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Standard 12 m vs baseline</td>
<td>0.3271</td>
<td>0.1564</td>
<td>0.6839</td>
<td>0.0030</td>
</tr>
<tr>
<td>Intensive vs standard and 3 m vs baseline</td>
<td>1.9367</td>
<td>0.3078</td>
<td>12.1870</td>
<td>0.4812</td>
</tr>
<tr>
<td>Intensive vs standard and 6 m vs baseline</td>
<td>4.4795</td>
<td>1.7081</td>
<td>11.7479</td>
<td>0.0023</td>
</tr>
<tr>
<td>Intensive vs standard and 12 m vs baseline</td>
<td>2.2861</td>
<td>0.8093</td>
<td>6.4579</td>
<td>0.1186</td>
</tr>
</tbody>
</table>

**E.1.1.5. Parent satisfaction:** Satisfaction score ranged from 1 to 5 (1 = very dissatisfied, 2 = dissatisfied, 3 = neutral, 4 = satisfied, and 5 = very satisfied). Patients in the intensive group experienced a slight but not significant ($P = 0.09$) reduction of 0.14 points in satisfaction score, while patients in the standard e-AT experienced a significant ($P < 0.001$) but minimal reduction of 0.24 points in satisfaction score. Overall, there was no difference ($P = 0.244$) between the 2 groups.

**E.1.1.6. ED/hospital admissions:** The average ED/hospital admission was 0.15 (0.50 SD) for the overall study population, and 0.22 (0.60 SD) during preintervention and 0.09 (0.35 SD) during postintervention. Compared with baseline, both intensive (RR [relative risk] = 0.12; 95% CI, 0.05-0.25; $P < 0.001$) and standard (RR = 0.08; 95% CI, 0.04-0.16; $P < 0.001$) interventions achieved a significant reduction in ED/hospital admissions. However, there was no difference ($P = 0.505$) in ED/hospital admissions between the 2 intervention groups.
E.1.2. Longitudinal Within-subject Analyses

These analyses assessed within-patient longitudinal change in outcomes (QOL, satisfaction, asthma control, interrupted/missed school days, and interrupted/missed work days) compared between baseline (prior to e-AT initiation) and follow-up assessments while using the e-AT.

**E.1.2.1. QOL:** Overall, average QOL scores were 79.1 at baseline and 90.9, 90.0, and 90.6 at 3, 6, and 12 months, respectively. The increase from baseline was the highest (12 points) at 3 months and then plateaued around 90 through the end of the study (Table 9). Patterns of increase ($P < 0.001$) in QOL scores occurred not only overall but also at almost all individual clinics (Figure 13 and Figure 14).
Table 9. Longitudinal Within-subject Analysis of QOL: Summary by Clinic and Timeline

<table>
<thead>
<tr>
<th></th>
<th>N</th>
<th>Mean</th>
<th>SD</th>
<th>Minimum</th>
<th>Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>970</td>
<td>86.78</td>
<td>12.92</td>
<td>20.00</td>
<td>100.00</td>
</tr>
<tr>
<td>Clinic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bryner</td>
<td>27</td>
<td>80.96</td>
<td>14.74</td>
<td>56.00</td>
<td>100.00</td>
</tr>
<tr>
<td>Hillcrest</td>
<td>114</td>
<td>82.35</td>
<td>14.73</td>
<td>40.00</td>
<td>100.00</td>
</tr>
<tr>
<td>Holladay</td>
<td>356</td>
<td>90.05</td>
<td>11.05</td>
<td>20.00</td>
<td>100.00</td>
</tr>
<tr>
<td>Johnson</td>
<td>90</td>
<td>89.51</td>
<td>9.13</td>
<td>60.00</td>
<td>100.00</td>
</tr>
<tr>
<td>Memorial</td>
<td>209</td>
<td>84.20</td>
<td>13.99</td>
<td>42.00</td>
<td>100.00</td>
</tr>
<tr>
<td>Redrock</td>
<td>15</td>
<td>95.20</td>
<td>7.28</td>
<td>80.00</td>
<td>100.00</td>
</tr>
<tr>
<td>Sandy</td>
<td>18</td>
<td>84.33</td>
<td>11.93</td>
<td>62.00</td>
<td>100.00</td>
</tr>
<tr>
<td>Southridge</td>
<td>33</td>
<td>80.91</td>
<td>14.52</td>
<td>52.00</td>
<td>100.00</td>
</tr>
<tr>
<td>UVProvo</td>
<td>108</td>
<td>85.92</td>
<td>13.29</td>
<td>42.00</td>
<td>100.00</td>
</tr>
<tr>
<td>Timeline</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>318</td>
<td>79.07</td>
<td>14.20</td>
<td>40.00</td>
<td>100.00</td>
</tr>
<tr>
<td>3 Months</td>
<td>218</td>
<td>90.98</td>
<td>9.54</td>
<td>46.00</td>
<td>100.00</td>
</tr>
<tr>
<td>6 Months</td>
<td>224</td>
<td>90.04</td>
<td>11.12</td>
<td>20.00</td>
<td>100.00</td>
</tr>
<tr>
<td>12 Months</td>
<td>210</td>
<td>90.64</td>
<td>10.34</td>
<td>42.00</td>
<td>100.00</td>
</tr>
</tbody>
</table>
Figure 13. Least squares means of change (x-axis) in QOL scores over time
**Figure 14. Change in QOL between different follow-up time and baseline score, and by clinic**

E.1.2.2. Asthma control: Average asthma control scores at baseline and quarters 1, 2, 3, and 4 were 18.8, 22.3, 22.8, 22.8, and 22.9, respectively, with the highest increase occurring in the first quarter and then plateauing at about 22 to 23 for the remaining follow-up quarters (Figure 15). Overall, asthma scores increased significantly ($P < 0.001$) in most clinics and across all follow-up quarters (Figure 16).

E.1.2.3. Interrupted/missed school days: The overall average number of interrupted/missed school days at baseline was 1.91, and 0.79, 0.52, and 0.79 at 3, 6, and 12 months, respectively, with the largest reduction occurring by 3-month follow-up. Reduction ($P < 0.001$) in the number of interrupted/missed school days was seen across most clinics (Figure 17) and follow-up schedules (Figure 18).
Figure 15. Least squares means of change (x-axis) in asthma control scores over time
Figure 16. Change in asthma control between different follow-up time and baseline score, and by clinic.

Change in adjusted mean of asthma score between baseline to different quarters.

- Bryner
- Hillcrest
- Holladay
- Johnson
- Memorial
- Redrock
- Sandy
- Southridge
- UVProvo
- Overall

Quarter: 1, 2, 3, 4
Figure 17. Least squares means of change (x-axis) in number of interrupted/missed school days over time
E.1.2.4. **Interrupted/missed work days:** The overall average number of interrupted/missed work days was 0.72 at baseline and 0.27, 0.25, and 0.19 at 3, 6, and 12 months, respectively, with the largest reduction occurring at 3-month follow-up. Reduction in the average number of interrupted/missed school days was seen ($P < 0.001$) at most clinics (Figure 19) and follow-up schedules (Figure 20).

E.1.2.5. **Parent satisfaction:** The overall average satisfaction score was 4.7 at baseline and was reduced (−0.21) to 4.5 points ($P < 0.001$) at 12 months (Figure 21). Fixed modeling analysis showed a significant reduction of points in satisfaction score. However, this reduction
in parent satisfaction was slight and not clinically meaningful, as the 12-month score (4.5) was still within the highest satisfaction range (4-5). (Note: satisfaction score addressed multiple facets of overall asthma care, beyond the influence of the e-AT). Also, when scores were dichotomized to > 3 vs ≤ 3, analyses showed no differences between baseline and 12-month scores.

Figure 19. Least squares means of change (x-axis) in number of interrupted/missed work days over time

![Graph showing least squares means of change in number of interrupted/missed work days over time. The x-axis represents time (months) from 0 to 12, and the y-axis represents the least squares mean number of work days interrupted or missed. Different lines represent different clinics (All clinic, Bryner, Hillcrest, Holladay, Johnson, Memorial, Southridge, UVProvo).]
Figure 20. Change in interrupted/missed work days between different follow-ups and baseline, and by clinic

Adjusted Rate Ratio of Interrupted/Missed work Days from baseline to different months

- Bryner
- Hillcrest
- Holladay
- Johnson
- Memorial
- Southridge
- UVProvo
- Overall

Month: 3, 6, 12
Figure 21. Change in parent satisfaction between different follow-ups and baseline, and by clinic

E.1.3. Comparisons of the Frequency of Hospital/ED Admissions and Oral Steroid Use Between the Year Following Each Patient’s Enrollment Visit and the Year Prior to the Enrollment Visit

The analysis compared overall hospital/ED admissions and oral steroid use in the study population (both standard and intensive e-AT), 1 year prior to initiation vs 1 year post-initiation of the e-AT.
**E.1.3.1. ED/hospital admissions:** The average ED/hospital admission was 0.15 (0.50 SD) overall, and 0.22 (0.60 SD) during preintervention and 0.09 (0.35) postintervention, and with an adjusted RR from preintervention to postintervention of 0.68 (95% CI, 0.49-0.95; \( P = 0.024 \)), demonstrating significant reduction in the postintervention period. At individual clinics, ED/hospital admissions were significantly reduced in 2 clinics and tended to have a lower RR (though not significant) at most of the remaining clinics (**Figure 22**), probably because of limited power.

**Figure 22. Adjusted rate ratio of ED/hospital admissions from preintervention vs postintervention, and by clinic**
**E.1.3.2. Steroid use:** The overall average oral steroid use was 0.63 (1.1 SD and 0.74 [1.2 SD]) days during preintervention and 0.51 (0.95 SD) days postintervention, and with an adjusted RR from preintervention to postintervention of 0.74 (95% CI, 0.61-0.91; \( P = 0.003 \)), demonstrating significant reduction in the postintervention period. At individual clinics, oral steroid use was significantly reduced in 2 clinics and tended to have a lower RR (although not significant) at most of the remaining clinics (Figure 23), probably because of limited power.

**E.1.4. Comparison of ED/Hospital Admissions and Oral Steroid Use Between Patients Enrolled in the 6 Early Starting Clinics vs Patients Enrolled in the 5 Late Starting Clinics, During Months 1 to 3 Delay**

This clinic-level (early vs late starting clinics) analysis compared oral steroid use and hospital/ED admissions between patients enrolled in the early starting clinics (clinics that started the e-AT on January 1, 2014, while late starting clinics were not using it) and patients enrolled in the late starting clinics (clinics that started the e-AT on April 1, 2014), during the 3-month delay period (between January 1, 2014, and March 31, 2014), used as usual care period. Although data were collected for 1 year prior to enrollment and 1 year following enrollment (see Section D.7), analysis was restricted to outcomes occurring during months 1 to 3 delay period (between January 1, 2014, and March 31, 2014). Only 2 participants had ED/hospital admissions and only 4 participants had steroid use during the 3-month period. Data were too sparse to be fitted for the LFE or GLME and the delay period was not long enough to have enough power for ED/hospital admissions.
E.1.5. Comparison of ED/Hospital Admissions and Oral Steroid Use 1-year Post-initiation of e-AT for Patients Who Started the Intervention Early to Those Who Started the e-AT Later, During a 1-year Period Prior to Starting the e-AT Intervention

This patient-level analysis compared rates of ED/hospital admissions and oral steroid use during 1-year post-e-AT initiation for patients who were enrolled in the first year (between January 2014 to December 2014, also known as early starting patients) and were using the e-AT (or were in the intervention period), with rates during a 1-year period prior to enrollment of
patients who were enrolled in the second year (between January 2015 to December 2015, or late starting patients), when they were not using the e-AT (usual care period).

**Rationale:** Subjects in the control group (late starting patients were receiving usual care) later became e-AT users (or met study eligibility criteria) and their pre-enrollment usual care time periods (including change in seasons) coincided with the post-enrollment time periods of those who enrolled early, limiting the confounding effects of seasonal change and secular trends in asthma care.

Due to sparseness of data (**Table 10**), we were not able to fit a GLME model with either fixed or random site effects to compare the rates of ED/hospital admissions and oral steroid use between the 2 groups. We had to combine all 1-year-prior-to-enrollment data for late starting participants and compare it to all 1-year-after-enrollment data for early starting participants. Overall, the average number of ED/hospital admissions was high, at 0.18 (0.57 SD) per year, in the late starting patients (during the time they were not exposed to the e-AT) and low, at 0.10 (0.38 SD) per year, in the early starting patients (during the time they were exposed to the e-AT). However, when comparing late vs early patients, this difference was not statistically significant ($P = 0.183$), with an RR of 1.74 (95% CI, 0.77-3.93). In addition, the average numbers of oral steroid use were similar, with 0.53 (0.92 SD) per year in the late starting patients and 0.53 (0.99 SD) per year in the early starting patients; we found no differences ($P = 0.937$) between the 2 groups.

**Table 10. Number of Early vs Late Starting Patients by Clinic**

<table>
<thead>
<tr>
<th>Start</th>
<th>Clinic</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Bryner</td>
<td>9</td>
<td>21</td>
<td>2</td>
<td>35</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>19</td>
<td>91</td>
<td></td>
</tr>
<tr>
<td>Late</td>
<td>Hillcrest</td>
<td>6</td>
<td>83</td>
<td>22</td>
<td>46</td>
<td>4</td>
<td>6</td>
<td>14</td>
<td>22</td>
<td>234</td>
<td></td>
</tr>
<tr>
<td>Early</td>
<td>Holladay</td>
<td>11</td>
<td>40</td>
<td>24</td>
<td>81</td>
<td>4</td>
<td>6</td>
<td>14</td>
<td>41</td>
<td>325</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>Johnson</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
E.1.6. Nonrandomized Comparison of Outcomes Between Patients From Randomized Clinics While Using the e-AT vs a Matched Control Cohort of Children With Persistent Asthma From Nonparticipating Clinics

The analyses in the preceding 2 sections allowed us to compare rates of poor asthma control in different periods, some in which e-AT was used and some in which it was not used. These comparisons of care outcomes with vs without e-AT at different times could be confounded by secular trends in asthma care. The nonrandomized comparison in this section addresses this potential bias. We compare asthma outcomes during the same periods in patients (cases) from randomized clinics that were using the e-AT to a matched control group of patients from nonparticipating clinics.

E.1.6.1. Comparison of ED/hospital admissions: There were 928 subjects (325 cases and 603 matched controls) for the analyses (Table 11). The overall average ED/hospital readmissions (per 1000 days) was 0.42 (1.36 SD) for cases and 0.23 (0.99 SD) for controls. Among cases, ED/hospital readmissions were 0.59 (1.64 SD) during the pre-e-AT period and 0.24 (0.97 SD) during the post-e-AT period. However, among controls, ED/hospital readmissions were 0.23 (1.01 SD) during pre-e-AT initiation and 0.24 (0.97 SD) during post-e-AT initiation. Random-effects analysis showed the ED/hospital readmissions for cases were significantly reduced among cases (RR: 0.43; 95% CI, 0.27-0.67; \(P = 0.0003\)) but not among controls (RR: 1.04; 95% CI, 0.69-1.58; \(P = 0.817\)). The intervention effect was RR: 0.41 (95% CI, 0.22-0.75; \(P = 0.0041\)).

E.1.6.2. Comparison of oral steroid use: Overall average oral steroid use (per 1000 patient days) was 1.71 (2.90 SD) for cases and 1.93 (6.0 SD) for controls. Among cases, oral steroid use was 2.02 (3.14 SD) during the pre-e-AT initiation and 1.41 (2.60 SD) during post-e-AT initiation. Among controls, oral steroid use was 1.87 (3.12 SD) during pre-initiation and 1.99 (7.89 SD) during post-initiation of the e-AT. Fixed-effects models showed the oral steroid use for cases was significantly reduced pre-initiation to post-initiation of e-AT among cases (RR: \(P = \ldots\))
0.69; 95% CI, 0.52-0.93; P = 0.0139) but not controls (RR: 1.06; 95% CI, 0.87-1.31; P = 0.5565).
The intervention effect was RR: 0.65 (95% CI, 0.46-0.93; P = 0.0191).

**E.1.7. Subgroup Analyses (Longitudinal Within-subject Analyses)**

We conducted the following subgroup analyses (see E.1.7.1 through E.1.7.4) on the overall study population, or 318 patients who received either standard or intensive e-AT intervention and completed baseline assessments.

**Table 11. Baseline Characteristics Between Cases and Matched Controls**

<table>
<thead>
<tr>
<th>Baseline Characteristics</th>
<th>Cases N (%)</th>
<th>Controls N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total N</strong></td>
<td>603</td>
<td>325</td>
</tr>
<tr>
<td><strong>PATIENT DEMOGRAPHICS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (mean [SD])</td>
<td>8.0 (3.9)</td>
<td>7.9 (4.0)</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>230 (38)</td>
<td>129 (39)</td>
</tr>
<tr>
<td>Male</td>
<td>373 (62)</td>
<td>196 (60)</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic/Latino</td>
<td>74 (2)</td>
<td>42 (14)</td>
</tr>
<tr>
<td>Not Hispanic/Latino</td>
<td>525 (87)</td>
<td>264 (85)</td>
</tr>
<tr>
<td>Unavailable</td>
<td>1 (0.2)</td>
<td>2 (1)</td>
</tr>
<tr>
<td>Declined to answer</td>
<td>3 (0.5)</td>
<td>2 (1)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Declined to answer</td>
<td>11 (2)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>48 (8)</td>
<td>79 (24)</td>
</tr>
<tr>
<td>Unknown</td>
<td>3 (0.5)</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>541 (90)</td>
<td>246 (76)</td>
</tr>
</tbody>
</table>

**E.1.7.1. QOL for Hispanic/Latino ethnicity:** Overall, average QOL scores were low (73.9 points) at baseline and increased to 87.3, 87.8, and 90.9 at 3, 6, and 12 months, respectively.
The increase \((P < 0.001)\) from baseline was 12.6 and 13.7 points at 3 and 6 months, with the highest increase of 16.6 points (higher than the increase observed in the overall study population) occurring at 12 months. We saw similar patterns of high improvements among other minority subgroups.

**E.1.7.2. Asthma control for Hispanic/Latino ethnicity:** Average asthma control scores were 17.3, 22.4, 22.8, 23.2, and 22.9, respectively, at baseline and at quarters 1, 2, 3, and 4, with the highest increase occurring by the first quarter and plateauing around 22 to 23 the remaining quarters, similar to the overall study population. The adjusted mean changes compared with baseline were 4.8, 5.1, 5.5, and 5.4 at quarters 1, 2, 3, and 4, respectively, and were constantly higher than the improvement seen in the overall study population, which was 3.0, 3.5, 3.5, and 3.6 at quarters 1, 2, 3, and 4, respectively. We also saw similar patterns of high improvements among other minority subgroups.

**E.1.7.3. QOL for patients with Medicaid insurance:** Overall, average QOL scores were low (76.0 points) at baseline and increased to 91.6, 89.1, and 87.7 at 3, 6, and 12 months, respectively. The increase \((P < 0.001)\) from baseline was 14.1, 12.9, and 11.3 points at 3, 6, and 12 months, respectively. The increase at 12 months was similar to that of the overall study subjects. We also saw similar patterns of high improvements among other minority subgroups.

**E.1.7.4. Asthma control for patients with Medicaid insurance:** Average asthma control scores at baseline and quarters 1, 2, 3, and 4 were 18.0, 22.2, 22.5, 22.3, and 23.6, respectively, with the highest increase occurring by the first quarter and then plateauing around 22 to 23 the remaining quarters, as seen in the overall study subjects. The adjusted mean change compared with baseline was 4.0, 4.4, 4.1, and 4.7 at quarters 1, 2, 3, and 4, respectively, and was constantly higher than improvement seen in the overall study subjects, which was 3.0, 3.5, 3.5, and 3.6 at quarters 1, 2, 3, and 4, respectively. We also saw similar patterns of improvements in other minority subgroups.
E.2. OBJECTIVE 2: Assess Whether the Effect on Child Outcomes Varies Across Parent Characteristics

**E.2.1. Demographics:** Analysis involved the overall study population (325 children), for which 53 (16.3%) had Medicaid coverage, 203 (62.5%) had private insurance, 5 (1.5%) were self-paying, and 64 (19.7%) had unknown insurance. The median number of children in these families was 3 (2,4 IQR [interquartile range]); 226 (83%) were from married families, and 243 (89%) had 1 member of the household with some college education (Table 12). Overall, average adherence (as measured by frequency of weekly use of the e-AT) to e-AT dropped in the first month and stabilized afterward. The overall average adherence was about 65% at the end of the 1-year study period, slightly lower in patients using the intensive e-AT vs those on standard e-AT intervention (Figure 24).

**E.2.2. Association of ED/hospital admissions (first admission) and frequency of e-AT use:** Of the 325 families included in the analysis, 212 (65.2%) were frequent and 113 (34.8%) infrequent e-AT users. Thirty-eight (18%) and 18 (16%) of frequent and infrequent e-AT users had first ED/hospital admissions during the study period. Reduction in ED/hospital readmissions among patients with private insurance was slightly higher (62%) when they were frequent e-AT users (HR [hazard ratio] = 0.38; 95% CI, 0.18-0.83; \( P = 0.02 \)); however, being infrequent users did not have this association. Overall, we found ED/hospital admissions varied by insurance coverage. Specifically, patients with private insurance were 60% less likely (HR = 0.40; 95% CI, 0.21-0.75; \( P = 0.005 \)) to have first ED/hospital readmission compared with those with Medicaid.
### Table 12. Family Demographics of Children With vs Without ED/Hospital Admissions

<table>
<thead>
<tr>
<th>Variables</th>
<th>Overall (N = 325)</th>
<th>Hospitalization/ED Admission</th>
<th>P Value</th>
<th>Testa</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No (N = 104)</td>
<td>Yes (N = 221)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of children (N = 53 missing) (median, interquartile range)</td>
<td>3 (2, 4)</td>
<td>3 (2, 4)</td>
<td>0.86</td>
<td>6</td>
</tr>
<tr>
<td>AGE (mean, SD)</td>
<td>7.9 (4.0)</td>
<td>8.6 (4.0)</td>
<td>0.03</td>
<td>7</td>
</tr>
<tr>
<td>MARITAL STATUS (missing N = 54)</td>
<td></td>
<td></td>
<td>0.20</td>
<td>3</td>
</tr>
<tr>
<td>Others</td>
<td>45 (17)</td>
<td>16 (21)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Married</td>
<td>226 (83)</td>
<td>59 (79)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EDUCATION (missing N = 52)</td>
<td></td>
<td></td>
<td>0.004</td>
<td>3</td>
</tr>
<tr>
<td>High school graduate or less</td>
<td>30 (11)</td>
<td>15 (20)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Some college or more</td>
<td>243 (89)</td>
<td>61 (80)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SEX</td>
<td></td>
<td></td>
<td>0.86</td>
<td>3</td>
</tr>
<tr>
<td>Female</td>
<td>129 (39)</td>
<td>42 (40)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>196 (60)</td>
<td>62 (60)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>INSURANCE</td>
<td></td>
<td></td>
<td>0.05</td>
<td>3</td>
</tr>
<tr>
<td>Medicaid</td>
<td>53 (16)</td>
<td>23 (22)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Private</td>
<td>272 (84)</td>
<td>81 (78)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ETHNICITY (missing N = 15)</td>
<td></td>
<td></td>
<td>0.08</td>
<td>4</td>
</tr>
<tr>
<td>Hispanic, Latino</td>
<td>42 (14)</td>
<td>19 (19)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not Hispanic or Latino</td>
<td>264 (85)</td>
<td>77 (79)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unavailable</td>
<td>2 (1)</td>
<td>1 (1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Declined to answer</td>
<td>2 (1)</td>
<td>1 (1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RACE</td>
<td></td>
<td></td>
<td>0.19</td>
<td>3</td>
</tr>
<tr>
<td>Others</td>
<td>79 (24)</td>
<td>30 (29)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>246 (76)</td>
<td>74 (71)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Test: 3=Chi-square, 4=Fisher, 6=Jonckheere-Terpstra, 7=ANOVA.L.trend
Figure 24. Average cumulative proportion of e-AT adherence (or use) by week

Note: The overall average adherence was about 65% at the end of the 1-year study period, slightly lower (but not significant) in patients who used the intensive e-AT vs those on Usual e-AT intervention. Usual group represents patients who received the standard e-AT intervention.

**E.2.3. Association of asthma control and frequency of e-AT use:** We found that child’s asthma control did not vary across education level and insurance coverage, and frequency of e-AT use did not change this relationship.

**E.2.4. Association of QOL and frequency of e-AT use:** Overall, we found that child’s QOL did not vary across education level and insurance coverage. However, parents with some college or more education had significantly reduced QOL (effect: −9.60; 95% CI, −15.35 to −3.85; *P* = 0.001) relative to those with high school graduate or less education, among those who were infrequent e-AT users.
E.3. OBJECTIVE 3: Determine Factors Associated With Sustained Parent Participation in Asthma Self-management

Analysis of individual univariate factors revealed that higher income ($\beta = 0.2343; SE = 0.0784; P = 0.0028$) was associated with sustained e-AT use, while being married ($\beta = -1.3327; SE = 0.4801; P = 0.0055$) and having high education ($\beta = -1.2596; SE = 0.6088; P = 0.0387$) were associated with less sustained e-AT use; however, none of these factors was significant in a multivariable model, when controlling for time-dependent intensive intervention. Further, analyses of open-ended questions revealed that improved management of asthma symptoms, provider and staff support, and use of gift card/incentives were the most common factors that facilitated use of e-AT in clinics, while lack of physician buy-in or staff support, and lack of time and e-AT integration with the electronic medical records were commonly reported barriers.
F. DISCUSSION

F.1. Decisional Context

When comparing clinics randomized to intensive vs standard e-AT, we found no statistical differences in all outcomes. We also found no differences in oral steroid use and ED/hospital admissions when comparing outcomes between early starting clinics and late starting clinics during the 3-month delay period. Similarly, we did not find any statistically significant differences (although late starting patients had higher ED/hospital readmissions) between early starting patients and late starting patients. However, when we compared outcomes between receiving the e-AT intervention relative and not receiving the e-AT (or usual care), we found clinically and statistically significant differences. Specifically, we found a significant improvement over time in outcomes from baseline (with no e-AT use) in either standard or intensive or both e-AT interventions overall (see Figures 9-12), as well as in individual clinics. We saw this change across all outcomes (except parent satisfaction), including improvement of child’s QOL and asthma control, reduction of child’s interrupted/missed school days and parent’s interrupted/missed work days, and reduction of child’s oral steroid use and ED/hospital admissions. Also, when comparing the year following patient’s e-AT enrollment to the year prior to enrollment, we found a significant reduction in oral steroid use and ED/hospital admissions overall, and in individual intervention arms, as well as at most clinics. Further, when comparing with matched controls from clinics that did not implement e-AT, we found participants from clinics that received e-AT interventions had significantly lower oral steroid use and ED/hospital admissions.

The current ambulatory asthma care model is reactive and inefficient, and focuses on episodic acute care, addressing treatment of recurrent asthma attacks. Our study is among the few to demonstrate multiple outcomes for the child, parent, and clinic can be improved through implementation of a potentially low-cost health information technology (the e-AT), promoting early identification of signs of asthma control deterioration to prompt timely
interventions. Our intervention represents a shift in ambulatory asthma care, from the current reactive acute care to a new model that is continuous and proactive, focusing on prevention of asthma attacks. Our results are helpful not only to families but also to health care providers, payers, and other community stakeholders willing to improve asthma care.

F.2. Study Results in Context

Previous studies have reported that adults who engage in effective self-management of a chronic disease have less activity limitation, improved QOL, improved perceived disease control, and improved medication adherence. However, self-management interventions in children with asthma remain rare. The few previous studies of self-management interventions have either not evaluated the effect on asthma outcomes or have reported mixed results with no effect or little effect on asthma outcomes, limiting their use in clinical practice. Our intervention is among the few to demonstrate a significant improvement in child, parent, and clinic outcomes. With the e-AT, improvements in asthma control and QOL exceed those previously reported. For instance, Voorend-van Bergen reported a 2-point change in ACT scores as the minimal important difference. In our e-AT intervention, improvement of ACT scores for patients who received the e-AT was 4 points already by the first quarter and was sustained through the end of the 12-month study period. Contrary to Rikkers-Mutsaerts’s study (consisted of weekly asthma control monitoring with the asthma control questionnaire and treatment advice by a web-based algorithm), which reported improvement in QOL at 3 but not 12 months, our study of e-AT, a web-based intervention, showed sustained QOL improvement throughout the study duration.

Studies have reported that parents often lack critical information and tools to guide them in recognizing and acting on warning signs. The e-AT has the potential to improve child asthma self-management, and thereby outcomes, by (1) increasing patient/parent roles in managing symptoms, including provision of self-care decision support; and (2) increasing awareness of chronic asthma symptoms through regular assessment and prompting patients to
seek appropriate and timely visits with their PCPs when chronic control is deteriorating instead of waiting until they experience a severe asthma attack.\textsuperscript{5,59-61} Ultimately, parents are empowered to recognize and act on early warning signs of declining asthma control or impending asthma attacks, including subtle symptoms that are usually missed. By increasing awareness of chronic asthma symptoms, the e-AT led to improved treatment of asthma, which ultimately resulted in better QOL and reduced use of acute health care services, potentially from optimal use of asthma medication.\textsuperscript{62}

Asthma guidelines recommend health care providers complete regular assessments of chronic asthma control, as it prompts timely and appropriate adjustments of therapy.\textsuperscript{6} However, studies continue to show that providers often lack or do not assess information about chronic asthma control. Lack of assessment results in failure to prescribe or appropriately adjust asthma therapy, leading to under treatment.\textsuperscript{63,64} Provider failure to assess asthma control is attributed to a busy schedule, lack of resources, limited ability and time to support ongoing monitoring outside clinical encounters, and lack of an effective follow-up process between regular clinic visits.\textsuperscript{63,64} The e-AT provides care providers with an effective way to monitor patients outside clinical encounters, providing real-time information about child asthma control status over time to capture early signs of deteriorations. Longitudinal information about a patient’s clinical status is available to the provider for use in medical decision making rather than the provider relying on one assessment at the time of an acute visit and patient/family recall.

Despite potential benefits, implementation of self-management interventions in clinical practice remains low, and their uptake by patients and patients’ adherence is often poor and declines significantly over time with high participant attrition.\textsuperscript{65,66} Van der Meer et al, for instance, reported a low adherence with weekly use of the ACQ for self-management of about 53% at 12 months.\textsuperscript{16} In our study, although adherence decreased over time, parent engagement remained high and stayed above 60% at the end of the 12-month study period. High adherence was likely due to our approach of providing training and support to primary
care providers’ offices to deliver the intervention themselves. Participants were motivated to comply with weekly use of the e-AT knowing that the PCP would examine their data (based on verbal communication with some participants and clinic staff).

F.3. Implementation of Study Results

Implementing e-AT at clinics requires a designated CCC and support from PCPs. In a typical clinic, asthma patients are identified (and approached) at the time of an office visit or by mail/phone invitation. Clinic personnel enroll the patient (providing training, connecting families to the e-AT), which takes about 30 minutes. Although not formally measured, ongoing monitoring is very efficient. For instance, in one clinic the CCC spent (30 to 40 minutes per week on average managing about 100 patients (this included receiving alerts, logging into the e-AT dashboard, reviewing the list of patients with low scores, making follow-up calls to identify and address issues, and scheduling an appointment with the PCP if needed). The e-AT dashboard has a tab that provides the list of patients (usually about 5 per week) with low scores (ie, ones that trigger an alert) for the CCC to follow up, allowing the CCC to quickly focus attention only on those in need of follow-up (rather than reviewing the data of each patient) and thereby minimizing workload.

Morrison et al reported that digital interventions are poorly described, with insufficient information about barriers and facilitators to their uptake and utilization. In our survey, the most important barriers to clinical staff adoption of e-AT in clinics were lack of physician buy-in and staff support. Clinic-level implementation needs to focus on securing PCP buy-in through education and training. The anticipated risks of e-AT use are minimal and primarily related to disclosure of protected health information. Fortunately, the e-AT has rigorous security protections as well as adherence to HIPAA privacy and data security requirements. Overall, we observed no adverse events.
F.4. Generalizability

The e-AT supports the use of evidence for best asthma care practices in the ambulatory care setting and helps meet self-management needs of not only children but also parents and PCPs. Also, our study showed outcome improvements with use of the e-AT among disadvantaged populations (see Section F.5), and the e-AT may be generalized to inner-city children who experience asthma care and outcome disparities. Therefore, dissemination of our e-AT care model can lead to major improvements in asthma care and outcomes, with potential reductions in asthma-related health care costs in the United States, and can serve as a model to improve care for other pediatric chronic diseases.

F.5. Subpopulation Considerations

Underserved populations, especially low-income Hispanic and black children, experience asthma care and outcome disparities compared with well-served populations. In our study, we found, among those who used the e-AT, that having Medicaid insurance (compared with private insurance) and low education level (compared with high education level) tended to be associated with shorter time to hospital readmission. Yet, we noted nonsignificant improvements for frequent e-AT users with Medicaid or low education level. Also, our subgroup analysis demonstrates that QOL and asthma control also significantly improved among Hispanic patients (the largest minority population in Utah), other minority patients, and those with Medicaid, who also achieved improvements that were higher across all follow-up quarters than the overall study population. Thus, disadvantaged populations seem to benefit more from this new care model, suggesting the e-AT might also be a tool to address asthma disparities among disadvantaged and minority populations.

F.6. Study Limitations

Our study has several limitations, resulting from the following:
We changed the design to compare intensive to standard e-AT interventions, rather than a randomized comparison of the e-AT intervention with usual care (control). We relied on several nonrandomized controls and pre–post comparisons to evaluate the e-AT effectiveness compared with usual care. Our study results should be interpreted with caution as unrecognized biases may have been introduced by using nonrandomized controls and pre–post comparisons. Thus, factors other than e-AT may be responsible of our results.

Enrollment was unbalanced across the clinics in the randomized comparison (standard vs intensive e-AT), with 3 of the 4 high patient-enrolling clinics (>20 patients per clinic) randomly assigned to the standard intervention and only 1 clinic assigned to the intensity intervention, leading to 60 enrolled patients in the standard intervention vs 60 enrolled patients in the intensive e-AT intervention. As a result, the power to estimate between-site variation in QOL and other outcomes was limited due to variable participant enrollment numbers across the clinics, particularly for statistical inferences under mixed models that account for intersite variation, and for nonnormally distributed outcomes. As a result, we also used fixed-effects analyses that applied statistical inferences specifically to participating clinics. However, when the fixed-effects approach is used, generalization of results from the current study sample to all other potential samples not in the study (beyond the specific enrolled clinics) may be limited. Applicability of results should be based on subject-matter considerations, since it depends on other unmeasured clinic factors.

Assignment of some (21%) patients to the standard e-AT prior to randomization led to different periods of postrandomization follow-up, adding complexity to the statistical analysis. Fortunately, 79% of the planned 1-year evaluation periods and all of the planned 12-month QOL assessments occurred after randomization, so the cost in statistical power incurred by variable evaluation periods after randomization was minimal.

We initially intended to use, but did not actually perform, multiple imputation analyses to address missing data. We instead used all available data in our analysis because missing data seemed to occur at random (however, we did not conduct formal analyses of
missingness). Therefore, our study results may be biased due to dropout rates that exceeded 10% in some outcomes.

F.7. Future Research

We plan to disseminate the e-AT across multiple clinics in Utah. We shared our results with Intermountain Healthcare leaders, and they have expressed interested in disseminating the e-AT care model in their system. We are discussing with them the potential for funding and resources needed to achieve this goal. We hope to use this opportunity to conduct a rigorous pragmatic study that will allow better comparison of e-AT effectiveness relative to usual care. Schools are an additional setting for dissemination, as the e-AT can support school nurses’ work to efficiently monitor many children with asthma, extending their reach to those from low socioeconomic households and racial/ethnic minorities experiencing asthma care disparities.

G. CONCLUSIONS

The new ambulatory care model supported by the e-AT was effective in engaging parents/children in sustained asthma self-management and was associated with improved asthma outcomes for patients, parents, and clinics. Dissemination of our new care model to more clinics can lead to major improvements in asthma care and outcomes, with potential reductions in asthma-related health care burden in the United States. The e-AT may also serve as a useful model for reducing asthma care disparities among underserved populations, a model that can be generalized to other pediatric chronic diseases. However, barriers to uptake and sustained use of such a care model in clinics need to be addressed for optimal benefits.
H. REFERENCES


2. CDC. National Health Interview Survey (NHIS) Data 2009.


62. Humbert M. The right tools at the right time. Chest 2006;130:29S-40S.


APPENDIX (Survey Questionnaire)

Parental/Guardian Sociodemographic Information

Why are we asking for this information?
The study your child is participating in will improve our understanding regarding the effectiveness of the electronic Asthma Tracker. The information obtained in this survey will also help us better understand the impact of other factors that are known to affect asthma symptom severity and participation in self-management. The information we collect will be coded so that it will NOT be associated with your name or anything else that might identify who gave the answers. If you do not feel comfortable answering a question, simply leave it blank. Thank you again for your participation.

Please check the box that appropriately describes you:

Respondent Information
What is your sex?
☐ Male
☐ Female

What is your relationship to the child enrolled in our study? _________________
Race/ethnicity
What is your race?
☐ White
☐ Black or African-American
☐ Hawaiian or Other Pacific Islander
☐ Asian or Asian American
☐ Multiple Races

What is your ethnicity?
☐ Hispanic
☐ Non-Hispanic

Marital status
Are you:
☐ Married
☐ Divorced
☐ Widowed
☐ Separated
☐ Never been married
☐ A member of an unmarried couple

Education completed
What is the highest grade or year of school you completed?
☐ Never attended school or only attended kindergarten
☐ Grades 1 through 8 (Elementary)
☐ Grades 9 through 11 (Some high school)
☐ Grade 12 or GED (High school graduate)
☐ College 1 year to 3 years (Some college of technical school)
☐ College 4 years (College graduate)
☐ Master’s Degree
☐ Doctoral Degree
☐ Professional Degree (MD, JD, etc.)
☐ Not applicable

What is the highest grade or year of school your spouse/partner has completed?
☐ Never attended school or only attended kindergarten
☐ Grades 1 through 8 (Elementary)

Household Income
☐ Under $25,000
☐ $25,000 - $39,999
☐ $40,000 - $49,999
☐ $50,000 - $74,999
☐ $75,000 - $99,999
☐ $100,000 - $124,999
☐ $125,000 - $149,999
☐ Over $150,000

Occupation (give examples)
☐ Management, business and financial operation
☐ Professional and related occupations
☐ Service occupations
☐ Sales and related occupations
☐ Office and administrative support
☐ Farming, fishing and forestry
☐ Construction, extraction and maintenance
☐ Production, transportation material moving
☐ Military specific occupations
☐ Not employed outside the home
☐ Other occupation

Family
How many children live in your household who are...
Less than 5 years old? _____
5 through 12 years old? _____
13 through 17 years old? _____
How many children who live in your household have been diagnosed with asthma? ____

What is the structure of your household?

- Child lives with both biological parents
- Single-parent home
- Combined (one biological parent, one step-parent)
- Adoptive Family
- Foster Family
- Other Describe: ___________

Language

What is the primary language spoken in the home?

- English
- Spanish
- Other Describe: ___________

Barriers to receiving health care

Please mark which if any of the following barriers relate to the way you access health care (check all that apply):

- Access to a vehicle
- Distance to travel
- Lack of free time
- Cost
- Health Insurance
- No Barriers
- Other
- Describe: ___________
CHILD’S QUALITY OF LIFE QUESTIONNAIRE (To be collected from the ADOLESCENT at enrollment, 3, 6 and 12 months)

(Adapted from the Integrated Therapeutics Group Child Asthma Short Form – ITG-CASF)

How often in the past 2 weeks...

1. Have you been short of breath? Would you say...
   none of the time...a little of the time...some of the time...most of the time...or all of the time?

2. Has strong physical activity, such as running, made it hard for you to breathe?
   none of the time...a little of the time...some of the time...most of the time...or all of the time

3. Have you coughed at night?
   none of the time...a little of the time...some of the time...most of the time...or all of the time

4. Have you woken up by wheezing or coughing?
   none of the time...a little of the time...some of the time...most of the time...or all of the time

5. Have you stayed indoors because of wheezing or coughing?
   none of the time...a little of the time...some of the time...most of the time...or all of the time

6. Has your education suffered due to your asthma during school?
   none of the time...a little of the time...some of the time...most of the time...or all of the time

7. Has your asthma interfered with your life?
   none of the time...a little of the time...some of the time...most of the time...or all of the time

8. Has your asthma limited your activities?
   none of the time...a little of the time...some of the time...most of the time...or all of the time

9. Have your parents had to make adjustments to family life because of your asthma?
   none of the time...a little of the time...some of the time...most of the time...or all of the time

10. Has taking your inhaler or other treatments interfered with your life?
    none of the time...a little of the time...some of the time...most of the time...or all of the time

   Additional Questions:
   In the past 3 months, have you ever missed days of school because of asthma?
   □ Yes  If yes, how many days? _____
   □ No
In the past 3 months, how many times have your parent(s) missed work due to your asthma? ____

□ Yes If yes, how many days? ____

□ No

**BEHAVIORAL FACTORS (to be completed by the ADOLESCENT at enrollment)**

**Scale:** Strongly Disagree (1) Disagree (2) Neither (3) Agree (4) Strongly Agree (5)

I have a good understanding of what my asthma symptoms are. (Knowledge/Understanding)
Answer: 1 2 3 4 5

I have a good understanding of what the triggers are for my asthma symptoms. (Knowledge/Understanding)
Answer: 1 2 3 4 5

I am good at recognizing when my asthma symptoms are under control or not under control. (Self-Efficacy)
Answer: 1 2 3 4 5

It bothers me when my asthma symptoms are not under control. (Attitudes/Beliefs)
Answer: 1 2 3 4 5

I am confident in my ability to keep my asthma symptoms under control. (Self-Efficacy)
Answer: 1 2 3 4 5

I am confident in my ability to recognize and adjust for triggers to my asthma symptoms. (Self-Efficacy)
Answer: 1 2 3 4 5

My parents help and support me in managing my asthma symptoms. (Family Support)
Answer: 1 2 3 4 5

My friends help and support me in managing my asthma symptoms. (Peer Support)
Answer: 1 2 3 4 5

I think it is important to manage my asthma symptoms as best as I can. (Attitudes/Beliefs)
Answer: 1 2 3 4 5

The time and effort it takes me to manage my asthma symptoms does **not** bother me too much. (Attitudes/Beliefs)
I think it is helpful for me to check my lung functioning every day. (Attitudes/Beliefs)
Answer: 1 2 3 4 5

It is important for me to track my asthma symptoms over time. (Attitudes/Beliefs)
Answer: 1 2 3 4 5

I like to learn about new and better ways to control my asthma symptoms. (Attitudes/Beliefs)
Answer: 1 2 3 4 5

It is important for me to regularly visit with a doctor or other medical professionals about my asthma symptoms. (Attitudes/Beliefs)
Answer: 1 2 3 4 5

I am able to choose for myself how I want to manage my asthma symptoms. (Autonomy/Control)
Answer: 1 2 3 4 5

My parents trust me to make good choices in how I manage my asthma symptoms. (Autonomy/Control)
Answer: 1 2 3 4 5

My doctor trusts me to make good choices in how I manage my asthma symptoms. (Autonomy/Control)
Answer: 1 2 3 4 5

TECHNOLOGY FACTORS (to be completed by the ADOLESCENT at enrollment, after using the Asthma Tracker for the first time and during the last survey at 12 months)

Scale: Strongly Disagree (1) Disagree (2) Neither (3) Agree (4) Strongly Agree (5)

Using the Asthma Tracker improves my ability to make good decisions about taking care of my asthma symptoms. (Usefulness)
Answer: 1 2 3 4 5

I am satisfied with the information I receive from the Asthma Tracker. (Information Satisfaction)
Answer: 1 2 3 4 5
The Asthma Tracker is easy to use. (Ease of Use)
Answer: 1 2 3 4 5

The Asthma Tracker provides me with all the information I need to monitor my asthma symptoms well. (Completeness)
Answer: 1 2 3 4 5

The information provided by the Asthma Tracker is clearly presented. (Format)
Answer: 1 2 3 4 5

The information provided by the Asthma Tracker is accurate. (Accuracy)
Answer: 1 2 3 4 5

The information from the Asthma Tracker is always up to date. (Currency)
Answer: 1 2 3 4 5

In general, the Asthma Tracker provides me with high-quality information. (Information Quality)
Answer: 1 2 3 4 5

The Asthma Tracker works reliably. (Reliability)
Answer: 1 2 3 4 5

The Asthma Tracker makes information to manage my asthma symptoms easy to find or access. (Accessibility)
Answer: 1 2 3 4 5

The Asthma Tracker provides information in a timely fashion. (Timeliness)
Answer: 1 2 3 4 5

OPEN ENDED QUESTIONS

1. What do you feel were the most important things that helped make it easy for you to use the electronic Asthma Tracker?

2. What do you feel were the most important things that got in the way of you effectively using the electronic Asthma Tracker?

Parent Satisfaction with Asthma Care
(Adapted from a previously validated measure 1-2)

1-5 Scale: 1= Very Dissatisfied, 5=Very Satisfied
1. The overall care your child has been receiving.

2. The relief from asthma symptoms your child has been receiving.

3. The quality of information that you have received about your child’s asthma disease.

4. The quality of the information that you have received about your child’s asthma treatment and the course of your child’s asthma disease.

5. How often you are updated about your child’s asthma disease and his/her health.

6. How well the providers and staff have been sensitive to your needs.

7. The willingness of the providers and staff to answer questions that you and your family may have.

8. The efforts to include your family in discussion of your child’s care and other information about your child’s asthma disease.

9. How well the providers and staff explained your child’s asthma disease and treatment to you in a way you could understand.

10. How well the providers and staff have explained your child’s asthma disease and treatment to your child in a way that she/he could understand.

11. How well the providers and staff listen to you and your concerns.

12. How well the providers and staff respond to your child’s needs.
Copyright© 2019. University of Utah. All Rights Reserved.

Disclaimer:

The [views, statements, opinions] presented in this report are solely the responsibility of the author(s) and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute® (PCORI®), its Board of Governors or Methodology Committee.

Acknowledgement:

Research reported in this report was [partially] funded through a Patient-Centered Outcomes Research Institute® (PCORI®) Award (#IH-12-11-5330) Further information available at: https://www.pcori.org/research-results/2013/does-advanced-electronic-tracker-help-families-manage-childrens-asthma